Go to main content
Harvard Business School
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Campaign
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions

Faculty & Research

  • HOME
  • FACULTY
  • RESEARCH
    • Global Research Centers
    • HBS Case Collection
    • HBS Case Development
    • Initiatives & Projects
    • Publications
    • Research Associate (RA) Positions
    • Research Services
    • Seminars & Conferences
    Close
  • FEATURED TOPICS
    • Business and Environment
    • Business History
    • Entrepreneurship
    • Finance
    • Globalization
    • Health Care
    • Human Behavior and Decision-Making
    • Leadership
    • Social Enterprise
    • Technology and Innovation
    Close
  • ACADEMIC UNITS
    • Accounting and Management
    • Business, Government and the International Economy
    • Entrepreneurial Management
    • Finance
    • General Management
    • Marketing
    • Negotiation, Organizations & Markets
    • Organizational Behavior
    • Strategy
    • Technology and Operations Management
    Close
Page Content

Richard G. Hamermesh

Senior Fellow, MBA Class of 1961 Professor of Management Practice, Retired

Photo of Richard G. Hamermesh

Unit: Entrepreneurial Management

Contact:

(617) 495-4179

Send Email

Richard Hamermesh is a Senior Fellow at the Harvard Business School where he was formerly the MBA Class of 1961 Professor of Management Practice. Currently, Richard is the faculty co-chair of the HBS/Kraft Precision Medicine Accelerator as well as the faculty co-chair of HBS’s new Executive Education program, Accelerating Innovation in Precision Medicine. 

Richard created and taught the second-year MBA elective, Building Life Science Businesses. Previously, he was the Course Head for the required first year course, The Entrepreneurial Manager.  In addition, Richard participates in several HBS Executive Education programs.

Richard was the founding Faculty Chair of the HBS Healthcare Initiative and has been instrumental in expanding the role of healthcare in MBA education and faculty research. Today, over 10% of students enrolled at Harvard Business School are pursuing careers in healthcare. 

From 1987 to 2001, Richard was a co-founder and a Managing Partner of The Center for Executive Development, an executive education and development consulting firm. Prior to this, from 1976 to 1987, he was a member of the faculty of the Harvard Business School.

Richard is also an active investor and entrepreneur, having participated as a principal, director, and investor in the founding and early stages of over 20 organizations. These have included start-ups, leveraged buy-outs, industry roll-ups, and non-profit foundations. He was the founding president of the Newton (MA) Schools Foundation and served on the editorial board of the Harvard Business Review. Richard has served on numerous Boards of Directors, and has chaired the Audit Committees of two public companies. He is currently on the Boards of three corporations. From 1991 to 1996, he was the founding Chairman of Synthes Spine, Inc.

Among his recent publications are: "What Precision Medicine Can Learn from the NFL" and "One Obstacle to Curing Cancer: Patient Data isn't Shared." Richard is the author or co-author of five books, including New Business Ventures and the Entrepreneur. His best-known book, Fad-Free Management, was published in 1996. He has published numerous articles and more than 100 case studies. Richard received his AB from the University of California, and his MBA and DBA from HBS. He is married, has two children, and four grandchildren. His hobbies include tennis, skiing, and yoga.

Featured Work

  1. What Cancer Researchers Can Learn from Direct-to-Consumer Companies

  2. One Obstacle to Curing Cancer: Patient Data Isn’t Shared

  3. Introducing the Kraft Precision Medicine Accelerator at Harvard Business School

  4. Making a Difference in Health Care at Harvard Business School

  5. A Microchip in Your Medicine

  6. The Long Run: the Impact of Brain Injuries on the NFL

Publications

Books

  1. Book | 2006

    New Business Ventures and the Entrepreneur

    Michael J. Roberts, Howard H. Stevenson, William A. Sahlman, Paul Marshall and Richard G. Hamermesh

    Keywords: Entrepreneurship;

    Citation:

    Roberts, Michael J., Howard H. Stevenson, William A. Sahlman, Paul Marshall and Richard G. Hamermesh, eds. New Business Ventures and the Entrepreneur. 6th ed. New York: McGraw-Hill/Irwin, 2006.  View Details
    CiteView DetailsFind at Harvard Related
  2. Book | 1996

    Fad-Free Management: The Six Principles That Drive Successful Companies and Their Leaders

    Richard G. Hamermesh

    Keywords: Management Practices and Processes;

    Citation:

    Hamermesh, Richard G. Fad-Free Management: The Six Principles That Drive Successful Companies and Their Leaders. Santa Monica, CA: Knowledge Exchange, 1996.  View Details
    CiteView DetailsFind at Harvard Related
  3. Book | 1986

    Business Policy: Text and Cases

    K. Andrews, J. Bower, C. R. Christensen, R. Hamermesh and M. E. Porter

    Keywords: Business Ventures; Corporate Strategy; Policy;

    Citation:

    Andrews, K., J. Bower, C. R. Christensen, R. Hamermesh, and M. E. Porter. Business Policy: Text and Cases. 6 Homewood, IL: Richard D. Irwin, 1986.  View Details
    CiteView Details Related
  4. Book | 1986

    Making Strategy Work: How Senior Managers Produce Results

    Richard G. Hamermesh

    Keywords: Management Teams; Strategy;

    Citation:

    Hamermesh, Richard G. Making Strategy Work: How Senior Managers Produce Results. New York: John Wiley & Sons, 1986.  View Details
    CiteView DetailsFind at Harvard Related
  5. Book | 1983

    Strategic Management

    Richard G. Hamermesh

    Keywords: Management Teams; Strategy;

    Citation:

    Hamermesh, Richard G., ed. Strategic Management. New York: John Wiley & Sons, 1983.  View Details
    CiteView DetailsFind at Harvard Related
  6. Book | 1982

    Business Policy: Text and Cases

    C. Roland Christensen, Kenneth R. Andrews, Joseph L. Bower, Richard G. Hamermesh and Michael E. Porter

    Keywords: Policy; Information; Cases;

    Citation:

    Christensen, C. Roland, Kenneth R. Andrews, Joseph L. Bower, Richard G. Hamermesh, and Michael E. Porter. Business Policy: Text and Cases. 5th ed. Homewood, IL: Richard D. Irwin, 1982.  View Details
    CiteView DetailsFind at Harvard Related

Journal Articles

  1. Article | Harvard Business Review (website)

    One Obstacle to Curing Cancer: Patient Data Isn't Shared

    Richard G. Hamermesh and Kathy Giusti

    Precision Medicine requires large datasets to identify the mutations that lead to various cancers. Currently, genomic information is hoarded in fragmented silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For new precision therapies to be developed, these data sets need to be shared broadly. Patients can help lead this effort by exercising their right to have their anonymized data made more broadly available.

    Keywords: healthcare; Technological and Scientific Innovation; Research and Development; Cancer care in the U.S.; cancer treatment; precision medicine; personalized medicine; data sharing; Technological Innovation; Data and Data Sets; Health Disorders; Medical Specialties; Research and Development; Customization and Personalization; Health Industry; United States;

    Citation:

    Hamermesh, Richard G., and Kathy Giusti. "One Obstacle to Curing Cancer: Patient Data Isn't Shared." Harvard Business Review (website) (November 28, 2016).  View Details
    CiteView Details Register to Read Related
  2. Article | Harvard Business Review

    Realizing the Promise of Personalized Medicine

    Mara G. Aspinall and Richard G. Hamermesh

    Keywords: Health;

    Citation:

    Aspinall, Mara G., and Richard G. Hamermesh. "Realizing the Promise of Personalized Medicine." Harvard Business Review 85, no. 10 (October 2007).  View Details
    CiteView DetailsFind at Harvard Related
  3. Article | Harvard Business Review

    Making Planning Strategic

    Richard G. Hamermesh

    Keywords: Planning; Strategy;

    Citation:

    Hamermesh, Richard G. "Making Planning Strategic." Harvard Business Review 64, no. 4 (July–August 1986): 115–120.  View Details
    CiteView DetailsFind at Harvard Related
  4. Article | Harvard Business Review

    Manage Beyond Portfolio Analysis

    Richard G. Hamermesh and Roderick E. White

    Keywords: Investment; Theory; Management;

    Citation:

    Hamermesh, Richard G., and Roderick E. White. "Manage Beyond Portfolio Analysis." Harvard Business Review 62, no. 1 (January–February 1984): 103–109.  View Details
    CiteView DetailsFind at Harvard Related
  5. Article | Academy of Management Review

    Toward a Model of Business Unit Performance

    Richard G. Hamermesh

    Keywords: Business Ventures; Performance;

    Citation:

    Hamermesh, Richard G. "Toward a Model of Business Unit Performance." Academy of Management Review 6, no. 2 (April 1981).  View Details
    CiteView DetailsFind at Harvard Related
  6. Article | Harvard Business Review

    How to Compete in Stagnant Industries

    Richard G. Hamermesh

    Keywords: Competition; Business Ventures;

    Citation:

    Hamermesh, Richard G. "How to Compete in Stagnant Industries." Harvard Business Review 57, no. 5 (September–October 1979).  View Details
    CiteView DetailsFind at Harvard Related
  7. Article | Harvard Business Review

    Strategies for Low Market Share Business

    Richard G. Hamermesh, M. Jack Anderson Jr. and J. Elizabeth Harris

    Keywords: Business Ventures;

    Citation:

    Hamermesh, Richard G., M. Jack Anderson Jr., and J. Elizabeth Harris. "Strategies for Low Market Share Business." Harvard Business Review 56, no. 3 (May–June 1978).  View Details
    CiteView DetailsFind at Harvard Related
  8. Article | Harvard Business Review

    Responding to Divisional Profit Crises

    Richard G. Hamermesh

    Keywords: Profit;

    Citation:

    Hamermesh, Richard G. "Responding to Divisional Profit Crises." Harvard Business Review 55, no. 2 (March–April 1977).  View Details
    CiteView DetailsFind at Harvard Related

Cases and Teaching Materials

  1. Teaching Note | HBS Case Collection | April 2018

    Hawk Electronics, Inc. (Brief Case)

    Richard G. Hamermesh and John J. Lafkas

    Citation:

    Hamermesh, Richard G., and John J. Lafkas. "Hawk Electronics, Inc. (Brief Case)." Harvard Business School Teaching Note 918-522, April 2018.  View Details
    CiteView DetailsPurchase Related
  2. Case | HBS Case Collection | April 2018

    Hawk Electronics, Inc.

    Richard G. Hamermesh and John J. Lafkas

    Citation:

    Hamermesh, Richard G., and John J. Lafkas. "Hawk Electronics, Inc." Harvard Business School Brief Case 918-521, April 2018.  View Details
    CiteView DetailsEducatorsPurchase Related
  3. Supplement | HBS Case Collection | January 2018

    The National Football League and Brain Injuries (B)

    Richard G. Hamermesh and George Riedel

    Citation:

    Hamermesh, Richard G., and George Riedel. "The National Football League and Brain Injuries (B)." Harvard Business School Supplement 818-082, January 2018.  View Details
    CiteView Details Related
  4. Case | HBS Case Collection | September 2017 (Revised December 2017)

    Intermountain Healthcare: Pursuing Precision Medicine

    Richard G. Hamermesh, Kathy E. Giusti, Robert S. Huckman and Julia Kelley

    Headquartered in Salt Lake City, Intermountain Healthcare operates 23 hospitals and hundreds of clinics in Utah and Idaho and provides insurance to approximately 850,000 patients through its insurance arm, SelectHealth. In 2013, Intermountain, known for its commitment to improving health care outcomes and lowering costs by reducing treatment variation, made the surprising decision to invest significant resources in an innovative precision medicine unit, which would provide life-extending, genetically targeted therapies to late-stage cancer patients. Precision medicine was associated with treatment variation and high costs, the latter being of particular concern given that Intermountain often served as both payer and provider for its patients. But Intermountain’s management was convinced by Lincoln Nadauld, MD, PhD, who joined Intermountain’s oncology team in 2013 and spearheaded the creation of Intermountain Precision Genomics (IPG). By 2016, IPG had a cutting-edge genomic sequencing laboratory that provided sequencing services to Intermountain and non-Intermountain physicians, and IPG’s team had conducted research indicating that targeted therapies administered through IPG extended patient lifespans but increased overall costs. Now, in mid-2017, IPG is undergoing a major transition as it prepares to outsource the bulk of its genomic testing volume to Navican Genomics, a for-profit, Intermountain-owned spinoff. As Nadauld contemplates the future of IPG, he must evaluate two exciting opportunities, and students are asked to consider where Nadauld should focus IPG’s resources: should IPG partner with Intermountain’s behavioral health team to conduct joint research on the relationship between genetic markers and antidepressant effectiveness, or should IPG push for the testing of a large biorepository, which will cost $12 million but could lead to the identification of new precision medicine applications? More broadly, students will also need to consider the ways in which IPG complements or conflicts with Intermountain’s mission and culture.

    Keywords: precision medicine; healthcare; innovation; entrepreneurship; cancer; cancer research; health care; technology; Health Care and Treatment; Innovation Leadership; Disruptive Innovation; Entrepreneurship; Decision Choices and Conditions; Health Industry; Insurance Industry; Utah; United States; North America;

    Citation:

    Hamermesh, Richard G., Kathy E. Giusti, Robert S. Huckman, and Julia Kelley. "Intermountain Healthcare: Pursuing Precision Medicine." Harvard Business School Case 818-018, September 2017. (Revised December 2017.)  View Details
    CiteView DetailsEducatorsPurchase Related
  5. Teaching Plan | HBS Case Collection | May 2017

    Neurotrack and the Alzheimer's Puzzle

    Richard G. Hamermesh and Carin-Isabel Knoop

    Teaching Note for HBS No. 816-072.

    Keywords: health care; Alzheimer's Disease; career path; life science business;

    Citation:

    Hamermesh, Richard G., and Carin-Isabel Knoop. "Neurotrack and the Alzheimer's Puzzle." Harvard Business School Teaching Plan 817-140, May 2017.  View Details
    CiteView DetailsPurchase Related
  6. Teaching Note | HBS Case Collection | May 2017

    The CRISPR-Cas9 Quarrel

    Richard G. Hamermesh and Matthew G. Preble

    Teaching Note for HBS No. 817-020.

    Citation:

    Hamermesh, Richard G., and Matthew G. Preble. "The CRISPR-Cas9 Quarrel." Harvard Business School Teaching Note 817-124, May 2017.  View Details
    CiteView DetailsPurchase Related
  7. Case | HBS Case Collection | September 2009 (Revised August 2012)

    Novasys Medical

    Richard G. Hamermesh and Lauren Barley

    Novasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the product for reimbursement. The case deals with the company's struggle to obtain a reimbursement code.

    Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Policy; Health Care and Treatment; Health Disorders; Product Development; Business and Government Relations; Medical Devices and Supplies Industry; United States;

    Citation:

    Hamermesh, Richard G., and Lauren Barley. "Novasys Medical." Harvard Business School Case 810-027, September 2009. (Revised August 2012.)  View Details
    CiteView DetailsEducatorsPurchase Related
  8. Case | HBS Case Collection | November 2016 (Revised November 2016)

    Radial Analytics Probes Post-Acute Care

    Richard G. Hamermesh and Olivia Hull

    Thaddeus Fulford-Jones and Eric Weiss, founders of healthcare technology startup Radial Analytics, have been busy developing a software program designed to save hospitals money and improve patient outcomes by producing customized care plans for patients leaving the hospital. Having piloted the program at an urban hospital in Massachusetts, they’re ready to disseminate the software to other accountable care organizations and bundled-payment hospitals. The case explores the issues the two entrepreneurs consider as they pursue the funding, clients, and business strategy that will allow them to scale their company and cut waste in Medicare spending.

    Keywords: electronic medical records; electronic health records; data science; Entrepreneurship; Health Care and Treatment; Business Model; Business Startups; Innovation and Invention; Growth Management; Marketing Strategy; Product Launch; Product Positioning; Science-Based Business; Business Strategy; Health Industry; Technology Industry; Cambridge; Massachusetts;

    Citation:

    Hamermesh, Richard G., and Olivia Hull. "Radial Analytics Probes Post-Acute Care." Harvard Business School Case 817-029, November 2016. (Revised November 2016.)  View Details
    CiteView DetailsEducatorsPurchase Related
  9. Case | HBS Case Collection | October 2016 (Revised January 2017)

    The CRISPR-Cas9 Quarrel

    Richard G. Hamermesh and Matthew G. Preble

    In mid-2016, the Broad Institute and the University of California, Berkeley were in the middle of a contentious patent dispute over which entity controlled a breakthrough gene editing technology called CRISPR-Cas9. With CRISPR-Cas9, scientists might soon be able to cure previously incurable genetic diseases such as sickle cell anemia and cystic fibrosis, among many others. The dispute had escalated to the point where the U.S. Patent and Trademark Office (USPTO) declared a patent interference and began a process to determine the intellectual property’s (IP) rightful owner. The USPTO’s decision would not only have serious commercial implications—the technology would be immensely important to biotechnology firms looking to develop gene therapy products and was, therefore, sure to generate strong revenues for whichever entity owned the IP—but would also essentially award scientific credit for this technology and thus impact the reputations of the scientists on both sides who had worked so hard to discover the tool. This case touches upon a number of other key issues, too: the ethical implications of gene editing; the state of IP and licensing in the biotechnology industry; the impact of lawsuits on developing new technologies and companies; and who should own platform technologies built, at least in part, by the research of multiple parties and government funding.

    Keywords: CRISPR; Broad Institute; University of California Berkeley; Intellectual Property; Patents; Law; Lawsuits and Litigation; Science; Genetics; Entrepreneurship; Biotechnology Industry; United States;

    Citation:

    Hamermesh, Richard G., and Matthew G. Preble. "The CRISPR-Cas9 Quarrel." Harvard Business School Case 817-020, October 2016. (Revised January 2017.)  View Details
    CiteView DetailsEducatorsPurchase Related
  10. Case | HBS Case Collection | October 2016 (Revised November 2016)

    Innovating Beyond Ochsner

    Richard G. Hamermesh and Olivia Hull

    The Ochsner Health System has developed a proprietary software tool designed to treat hypertension. Built into the system’s electronic medical records, the Hypertension Digital Medicine program allows patients to record their blood pressure at home and share readings with their medical providers in real time. A year and a half after launching the program, the health system’s internal startup, innovationOchsner, has gathered promising clinical results and validation from the medical community. The case explores the challenges Ochsner faces in scaling and disseminating the program to other healthcare providers.

    Keywords: electronic medical records; telemedicine; hypertension; high blood pressure; chronic disease; Entrepreneurship; Health Disorders; Business Model; Business Startups; Innovation and Invention; Growth Management; Marketing Strategy; Product Launch; Product Positioning; Science-Based Business; Business Strategy; Health Industry; Technology Industry; New Orleans; Louisiana;

    Citation:

    Hamermesh, Richard G., and Olivia Hull. "Innovating Beyond Ochsner." Harvard Business School Case 817-028, October 2016. (Revised November 2016.)  View Details
    CiteView DetailsEducatorsPurchase Related
  11. Teaching Note | HBS Case Collection | September 2016

    Mohamed Azab and Seha Capital

    Richard Hamermesh and Sarah McAra

    Teaching Note for case 816-066.

    Keywords: Egypt;

    Citation:

    Hamermesh, Richard, and Sarah McAra. "Mohamed Azab and Seha Capital." Harvard Business School Teaching Note 817-039, September 2016.  View Details
    CiteView DetailsPurchase Related
  12. Case | HBS Case Collection | February 2016 (Revised August 2016)

    Neurotrack and the Alzheimer's Puzzle

    Richard G. Hamermesh, Liz Kind and Carin-Isabel Knoop

    Elli Kaplan founded Neurotrack in 2012 with a breakthrough noninvasive cognitive diagnostics test that will detect Alzheimer's disease in its earliest pre-symptomatic stages. While the company has gained great traction in the three years since it was started, with no therapeutic product available in the foreseeable future, Kaplan is considering whether it is time to change the company's business model.

    Keywords: Alzheimer's Disease; diagnostics; healthcare; Entrepreneurship; Health; Science-Based Business; Medical Devices and Supplies Industry; United States;

    Citation:

    Hamermesh, Richard G., Liz Kind, and Carin-Isabel Knoop. "Neurotrack and the Alzheimer's Puzzle." Harvard Business School Case 816-072, February 2016. (Revised August 2016.)  View Details
    CiteView DetailsEducatorsPurchase Related
  13. Case | HBS Case Collection | February 2016 (Revised August 2016)

    Mohamed Azab and Seha Capital

    Richard G. Hamermesh and Sarah McAra

    In January 2011, Mohamed Azab, founder and CEO of health care investment firm Seha Capital, made his first health care investment in Hassab Labs, a diagnostic lab in Alexandria, Egypt. Weeks later, a revolution erupted across the country as the Arab Spring swept through the region, and Azab spent the following years active in both the protests and in restructuring and expanding Hassab Labs. From 2011 to 2014, he opened 25 new branches, quadrupled staff, and more than doubled net income. By the end of the revolution in 2014, Hassab Labs was among the top five chains in the country. In October 2014, Seha partially exited Hassab Labs in a sale to an African conglomerate, SAHAM Group. At the same time, Azab learned that foreign investors in a small private hospital in Egypt were looking to exit the market. While Seha's mission was to build diagnostic, hospital, and pharmacy chains in Egypt, Azab had not been planning to enter the hospital market until he further expanded the diagnostic labs. In late 2014, Azab must decide if he should focus on expanding Hassab Labs, either in Egypt or across Africa, or invest in the hospital.

    Keywords: health care; health; entrepreneurship; pan-Africa; health care investment; financing; developing world; Entrepreneurship; Egypt; Africa;

    Citation:

    Hamermesh, Richard G., and Sarah McAra. "Mohamed Azab and Seha Capital." Harvard Business School Case 816-066, February 2016. (Revised August 2016.)  View Details
    CiteView DetailsEducatorsPurchase Related
  14. Teaching Plan | HBS Case Collection | July 2015

    Medalogix

    Richard G. Hamermesh and Matthew G. Preble

    Citation:

    Hamermesh, Richard G., and Matthew G. Preble. "Medalogix." Harvard Business School Teaching Plan 816-012, July 2015.  View Details
    CiteView DetailsPurchase Related
  15. Supplement | HBS Case Collection | June 2015

    MINTing Innovation at NewYork-Presbyterian (B)

    Richard G. Hamermesh and Michael Norris

    This short (B) case gives an update on the progress that MINT has made at NYP since the end of the (A) case.

    Citation:

    Hamermesh, Richard G., and Michael Norris. "MINTing Innovation at NewYork-Presbyterian (B)." Harvard Business School Supplement 815-113, June 2015.  View Details
    CiteView DetailsPurchase Related
  16. Teaching Plan | HBS Case Collection | June 2015

    Bloodbuy

    Richard Hamermesh, John Quelch and Michael Norris

    Citation:

    Hamermesh, Richard, John Quelch, and Michael Norris. "Bloodbuy." Harvard Business School Teaching Plan 815-140, June 2015.  View Details
    CiteView DetailsPurchase Related
  17. Teaching Plan | HBS Case Collection | June 2015

    The National Football League and Brain Injuries

    Richard G. Hamermesh and Matthew Preble

    Citation:

    Hamermesh, Richard G., and Matthew Preble. "The National Football League and Brain Injuries." Harvard Business School Teaching Plan 815-134, June 2015.  View Details
    CiteView DetailsPurchase Related
  18. Case | HBS Case Collection | March 2015

    Bloodbuy

    Richard G. Hamermesh and Michael Norris

    In 2015, Chris Godfrey, founder and CEO of Bloodbuy, has to consider the best path to growth for his young company, which is attempting to disrupt the blood donation industry.

    Keywords: health care; health care entrepreneurship; Blood donation; Health Care and Treatment; Entrepreneurship; Health Industry; United States;

    Citation:

    Hamermesh, Richard G., and Michael Norris. "Bloodbuy." Harvard Business School Case 815-114, March 2015.  View Details
    CiteView DetailsEducatorsPurchase Related
  19. Case | HBS Case Collection | March 2015 (Revised June 2015)

    Medalogix

    Richard G. Hamermesh and Matthew G. Preble

    This case examines an exciting new approach to health care that will help care providers identify when hospice services are the appropriate type of care for patients. The company, Medalogix, already has a product on the market that uses a proprietary algorithm to consider dozens of factors and determine when a patient qualifies for a hospice care eligibility review. The product has started to gain traction, and the case explores how Medalogix can scale and disseminate its innovative product.

    Keywords: health care; health care entrepreneurship; health care services; Implementing strategy; dissemination; innovation; market selection; Health; Health Care and Treatment; Data and Data Sets; Marketing Strategy; Innovation and Management; Innovation Strategy; Health Industry; United States;

    Citation:

    Hamermesh, Richard G., and Matthew G. Preble. "Medalogix." Harvard Business School Case 815-116, March 2015. (Revised June 2015.)  View Details
    CiteView DetailsEducatorsPurchase Related
  20. Supplement | HBS Case Collection | February 2015 (Revised November 2015)

    Building an Integrated Biopharma Company: Crucell (B)

    Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling

    The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8 billion.

    Keywords: biotechnology; biopharmacy company; licensing agreements in biopharmacy; licensing; human cell-line technology; vaccine; healthcare innovation; Global health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Biotechnology Industry; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., Marianne Van Der Steen, and Susan Harmeling. "Building an Integrated Biopharma Company: Crucell (B)." Harvard Business School Supplement 815-086, February 2015. (Revised November 2015.)  View Details
    CiteView DetailsPurchase Related
  21. Case | HBS Case Collection | February 2015 (Revised November 2015)

    Building an Integrated Biopharma Company: Crucell (A)

    Richard G. Hamermesh, Marianne Van Der Steen and Susan S. Harmeling

    By 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space, had begun to attract the attention of much larger pharmaceutical companies. While there was much appeal to working with these companies, these relationships could also challenge Crucell's independence. This issue is highlighted by the decision whether to partner with companies that wanted ownership of 10-20% of Crucell as part of the business development deals.

    Keywords: biotechnology; biopharmacy company; licensing; licensing agreements in biopharmacy; human cell-line technology; vaccine; healthcare innovation; Global health; Partners and Partnerships; Entrepreneurship; Growth and Development Strategy; Biotechnology Industry; Pharmaceutical Industry; Netherlands;

    Citation:

    Hamermesh, Richard G., Marianne Van Der Steen, and Susan S. Harmeling. "Building an Integrated Biopharma Company: Crucell (A)." Harvard Business School Case 815-085, February 2015. (Revised November 2015.)  View Details
    CiteView DetailsEducatorsPurchase Related
  22. Case | HBS Case Collection | October 2014 (Revised June 2015)

    The National Football League and Brain Injuries

    Richard G. Hamermesh and Matthew G. Preble

    The National Football League (NFL) was both the most popular spectator sport in the U.S. and a major economic entity, taking in roughly $10 billion a year in revenue. However through the early twenty-first century, an increased understanding of the long-term effects of head injuries on NFL players indicated a serious threat to the long-term viability of the game. Particularly concerning was the indication that some deceased professional football players had developed chronic traumatic encephalopathy (CTE)—a neurodegenerative disease which had a strong influence on a person's mental and physical health—most likely as a result of repetitive hits sustained during their football careers and which may have contributed to their deaths.
    Over 4,000 retired players had jointly sued the NFL over the head injuries they had sustained during their time in the NFL and the resulting health problems they attributed to these injuries. In part, the lawsuit alleged that the NFL had not been forthcoming with players about the health risks of head injuries. The two sides had reached a tentative $765 million settlement in 2013, the bulk of which would go to compensating retired players suffering from such diseases as Alzheimer's or dementia.
    While this settlement compensated retired players, it was not applicable to current or future players. Could the NFL preserve the sport by making it safer through new rules or equipment changes, or was football an inherently physical game that no amount of new rules or equipment could make completely safe? Were current and future players, now knowing full well the potential long-term health implications of football, tacitly accepting the risks involved? As a team owner, is now the time to sell while franchise value and fan support are at their peaks, or will the business of the NFL be viable for years to come?

    Keywords: employee safety; Safety; Employees; Sports; Health; Sports Industry; United States;

    Citation:

    Hamermesh, Richard G., and Matthew G. Preble. "The National Football League and Brain Injuries." Harvard Business School Case 815-071, October 2014. (Revised June 2015.)  View Details
    CiteView DetailsEducatorsPurchase Related
  23. Case | HBS Case Collection | June 2014 (Revised February 2017)

    Kathy Giusti and the Multiple Myeloma Research Foundation

    Richard G. Hamermesh, Joshua D. Margolis and Matthew G. Preble

    What do you do when your rising professional career is cut short by an unexpected cancer diagnosis? Kathy Giusti shifted careers, built a new organization that transformed how cancer research is done, and now faces the challenge of sustaining the organization and its funding for its newest venture.

    Since she was first diagnosed with multiple myeloma (MM) in 1996, Giusti had led an effort to better understand and treat the disease. She had co-founded the Multiple Myeloma Research Foundation (MMRF), helped form the Multiple Myeloma Research Consortium (MMRC), and brought together a diverse body of academics, researchers, pharmaceutical and biotech companies, physicians, and patients to combine their efforts around the disease. The MMRF had helped facilitate clinical trials for promising drugs, sponsored research, and raised a substantial amount of money for these purposes.

    In 2014, the MMRF was in the midst of its CoMMpass program; a multi-year effort to collect tissue samples from 1,000 patients at key junctures in their disease, sequence these samples to better understand the genetic underpinnings of MM and its many sub-types, and thus enable researchers to study a comprehensive sampling of patients. CoMMpass also had a patient-facing element which allowed the patient community to communicate with one another and with professional moderators. By mid-2014, some 550 patients were enrolled and 85 hospitals were participating.

    As a non-profit, the MMRF had historically relied on donations to fund its research operations. Giusti wanted to find a way to ensure a reliable revenue stream for the organization and give it greater financial stability. The MMRF had historically given away its resources and knowledge for free in order to speed research; Giusti worried if charging for some of its functions would be at odds with its mission and historical practices. She worked with her executive team to examine potential sources of revenue, and to decide if this was the right thing to do.

    Keywords: leadership; philanthropy; philanthropy funding; entrepreneurship; health care; management styles; management skills; personalized medicine; health care outcomes; cancer; Cancer care in the U.S.; personal care; Leading Change; Social Entrepreneurship; Philanthropy and Charitable Giving; Health Care and Treatment; Leadership Style; Management Style; Growth and Development Strategy; Business Strategy; Health; Health Industry; United States; Canada; Spain;

    Citation:

    Hamermesh, Richard G., Joshua D. Margolis, and Matthew G. Preble. "Kathy Giusti and the Multiple Myeloma Research Foundation." Harvard Business School Case 814-026, June 2014. (Revised February 2017.)  View Details
    CiteView DetailsEducatorsPurchase Related
  24. Course Overview Note | July 2014 (Revised January 2017)

    Building Life Science Businesses Spring Term 2017: Course Outline and Syllabus

    Richard G. Hamermesh

    This Course Outline and Syllabus gives an overview of the Spring 2016 class Building Life Science Businesses.7

    Keywords: healthcare ventures; entrepreneurial management; entrepreneurship; entrepreneurs; Health Care and Treatment; Health Testing and Trials; Medical Specialties; Health Industry; Biotechnology Industry; Medical Devices and Supplies Industry; Asia; North America; Europe;

    Citation:

    Hamermesh, Richard G. "Building Life Science Businesses Spring Term 2017: Course Outline and Syllabus." Harvard Business School Course Overview Note 815-003, July 2014. (Revised January 2017.)  View Details
    CiteView DetailsPurchase Related
  25. Case | HBS Case Collection | March 2014 (Revised June 2014)

    salaUno: Eliminating Needless Blindness in Mexico

    Richard Hamermesh, Regina Garcia Cueller and Valeria Moy

    In May 2013 the co-founders and co-CEOs of salaUno, Javier Okhuysen and Carlos Orellana, were encouraged by the results of their fledgling start-up. salaUno was founded as a for-profit enterprise in order to have the capital needed for rapid growth and to fulfill its mission of Eliminating Needless Blindness in Mexico. salaUno had grown from doing 75 cataract surgeries in its first month of operation to a high of 388 surgeries 21 months later. This case explores the challenges in scaling up a healthcare venture within a developing country.

    Keywords: medical services; developing countries; developing markets; health care industry; health services; healthcare ventures; healthcare startups; Health Care and Treatment; Health; Medical Specialties; Developing Countries and Economies; Health Industry; Mexico; Mexico City;

    Citation:

    Hamermesh, Richard, Regina Garcia Cueller, and Valeria Moy. "salaUno: Eliminating Needless Blindness in Mexico." Harvard Business School Case 814-041, March 2014. (Revised June 2014.)  View Details
    CiteView DetailsEducatorsPurchase Related
  26. Supplement | HBS Case Collection | January 2014

    Fred Khosravi and AccessClosure (C)

    Richard Hamermesh and Lauren Barley

    On September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the company. The future looked bright for AccessClosure as 2013 drew to a close. The company expected 2014 revenues of more than $100 million with a gross margin of greater than 70%. It was also anticipating FDA approval on a significant product improvement within the next several months.

    Keywords: medical devices; vascular closure device; patent litigation; Patenting; Biotechnology Industry; Biomedical Research; biotechnology; biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States;

    Citation:

    Hamermesh, Richard, and Lauren Barley. "Fred Khosravi and AccessClosure (C)." Harvard Business School Supplement 814-074, January 2014.  View Details
    CiteView DetailsPurchase Related
  27. Teaching Plan | HBS Case Collection | January 2014

    MedImmune Ventures

    Richard Hamermesh and Andrew Otazo

    "MedImmune Ventures" highlights the problems faced by corporate venture capital firms, the challenges of investing in early-stage healthcare, and the difficulty of operating in distant markets.

    Keywords: MedImmune Ventures; NeuProtect; Corporate Venture Capital; venture capital; Ron Laufer; Australia; Starfish Ventures; AstraZeneca; MEVE; healthcare; Startup; Venture Capital; Business Startups; Health Industry; Australia; United States;

    Citation:

    Hamermesh, Richard, and Andrew Otazo. "MedImmune Ventures." Harvard Business School Teaching Plan 814-039, January 2014.  View Details
    CiteView DetailsPurchase Related
  28. Case | HBS Case Collection | January 2014 (Revised December 2014)

    GenapSys: Business Models for the Genome

    Richard G. Hamermesh, Joseph B. Fuller and Matthew Preble

    GenapSys, a California-based startup, was soon to release a new DNA sequencer that the company's founder, Hesaam Esfandyarpour, believed was truly revolutionary. The sequencer would be substantially less expensive—potentially costing just a few thousand dollars—and smaller than other sequencers, many of which were large devices costing tens of thousands or hundreds of thousands of dollars. GenapSys' device, named GENIUS, could also quickly generate large amounts of data, as it was capable of sequencing an entire human genome in less than eight hours. At this price, GenapSys' device would be attractive to customers that had been unable to afford sequencers, such as smaller laboratories or hospitals, and even expand the market to include industries such as agriculture and biofuels.

    As GenapSys came closer to releasing its product, Esfandyarpour and his Senior Director of Operations and Strategy, Leila Rastegar (HBS '11), sat down to decide which of three business models they would choose to bring this device to market. In the first model, the company would sell sequencers at a higher price to those entities which already purchased sequencers, primarily major research labs and pharmaceutical firms, but position its machine as a faster alternative to existing technologies. In the second model, GenapSys would sell its sequencer at a lower price but charge more for the cartridges necessary to run a sample, and earn its primary revenue from these cartridges. The third model would see GenapSys sell its device at or around cost, but use the data customers generated to create a proprietary database of genetic information. Customers could pay to access the database for research, to create genetic tests, or for many other purposes. GenapSys would also build an online store with the genetic tests customers created.

    Esfandyarpour's and Rastegar's decision would determine GenapSys' customer base and financial position for the coming years, and also impact development and capital needs of the firm. Which was the right model to bring the device to market and have a meaningful impact?

    Keywords: DNA Sequencing; life sciences; business model; innovation & entrepreneurship; Health Care and Treatment; Genetics; Business Strategy; Biotechnology Industry; Pharmaceutical Industry; Technology Industry; Health Industry; Medical Devices and Supplies Industry; United States;

    Citation:

    Hamermesh, Richard G., Joseph B. Fuller, and Matthew Preble. "GenapSys: Business Models for the Genome." Harvard Business School Case 814-050, January 2014. (Revised December 2014.)  View Details
    CiteView DetailsEducatorsPurchase Related
  29. Case | HBS Case Collection | October 2013

    FasterCures: Removing Barriers to Treatments

    Richard G. Hamermesh and James Weber

    In mid-2013, as FasterCures celebrated its 10th anniversary as a center of the Milken Institute, Executive Director Margaret Anderson thought about what the organization should do to ensure it had even more impact in its next 10 years. FasterCures was a non-profit "action tank" whose mission was to speed up the process of moving new therapies from discovery to patients in need. Although their annual conference ("Partnering for Cures") to improve how government research was organized was a huge success, Anderson considered refocusing their resources on greater challenges.

    For example, current trends in the US showed that investors were increasingly supporting late stage research with higher probabilities of success while funding for riskier early stage research was drying up. Should FasterCures raise money and direct it toward early stage breakthrough therapies? Another issue was the US clinical trial process system. It's complicated, takes a long time, and is very expensive. Should FasterCures reorganize to better understand this issue and make a high-level push to improve it? Or perhaps FasterCures should look at drug reimbursement decisions. Anderson needed to determine where FasterCures should get fully involved, what it should do, and whether it could make a difference.

    Keywords: health; health care; health care industry; health care policy; health services; healthcare; healthcare reform; healthcare ventures; nonprofit; non-profit management; not-for-profit; incubator; accelerator; venture philanthropy; medical services; medical solutions; medical research; medical treatment; clinical trials; drug reimbursement; early stage; early stage research funding; early stage funding; Milken Institute; Michael Milken; David Baltimore; Partnering for Cures; National Institutes of Health; Cancer care in the U.S.; Cancer care services; policy-making; Health Care and Treatment; Health; Health Testing and Trials; Entrepreneurship; Social Entrepreneurship; Nonprofit Organizations; Policy; Health Industry; United States; District of Columbia;

    Citation:

    Hamermesh, Richard G., and James Weber. "FasterCures: Removing Barriers to Treatments." Harvard Business School Case 814-003, October 2013.  View Details
    CiteView DetailsEducatorsPurchase Related
  30. Supplement | HBS Case Collection | October 2013 (Revised January 2014)

    Fred Khosravi and AccessClosure (B)

    Richard G. Hamermesh and Lauren Barley

    It was January 2013, and Fred Khosravi, chairman of the board of AccessClosure Inc., wondered what the new year had in store for him and AccessClosure, the company he founded in late 2002. Khosravi was cautiously optimistic—the Mountain View, California-based medical device company had been cash flow positive for seven consecutive quarters with annual revenues over $70 million. Since 2007, it had shipped well over 1.5 million of its vascular closure device (VCD), the Mynx, which was stocked in more than 1,200 catheter labs worldwide. However, a 2008 patent infringement lawsuit filed by St. Jude Medical, the VCD market leader, loomed large. The case was on appeal, and a three-judge panel would hear arguments in March 2013. If AccessClosure lost its appeal, it faced a $27.1 million judgment for patent infringement and a permanent injunction from selling its Mynx family of VCDs, its sole source of revenue.

    Keywords: medical devices; vascular closure device; patent litigation; Patenting; Biotechnology Industry; Biomedical Research; biotechnology; biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States; California;

    Citation:

    Hamermesh, Richard G., and Lauren Barley. "Fred Khosravi and AccessClosure (B)." Harvard Business School Supplement 814-038, October 2013. (Revised January 2014.)  View Details
    CiteView DetailsPurchase Related
  31. Case | HBS Case Collection | August 2013 (Revised October 2013)

    MedImmune Ventures

    Richard G. Hamermesh and David Lane

    Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer will make will reflect his vision for MedImmune Ventures and more broadly the incentives he faces as a corporate venture capitalist.

    Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; corporate venturing; venture capital; biotechnology; venture investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London;

    Citation:

    Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)  View Details
    CiteView DetailsEducatorsPurchase Related
  32. Course Overview Note | August 2013

    Building Life Science Businesses Fall 2013: Course Outline and Syllabus

    Richard G. Hamermesh

    This Course Outline and Syllabus gives an overview of the Fall 2013 class Building Life Science Businesses.

    Keywords: healthcare ventures; entrepreneurial management; entrepreneurship; entrepreneurs; Health Care and Treatment; Health Testing and Trials; Medical Specialties; Health Industry; Biotechnology Industry; Medical Devices and Supplies Industry; Asia; North America; Europe;

    Citation:

    Hamermesh, Richard G. "Building Life Science Businesses Fall 2013: Course Outline and Syllabus." Harvard Business School Course Overview Note 814-019, August 2013.  View Details
    CiteView DetailsPurchase Related
  33. Course Overview Note | January 2013 (Revised January 2013)

    The Entrepreneurial Manager: Course Overview, 2013 Winter Term

    Richard G. Hamermesh, Richard G. Hamermesh and Thomas Eisenmann

    Course overview of The Entrepreneurial Manager.

    Keywords: Entrepreneurship; Management; Business Education;

    Citation:

    Hamermesh, Richard G., and Thomas Eisenmann. "The Entrepreneurial Manager: Course Overview, 2013 Winter Term". Harvard Business School Course Overview Note 813-155, January 2013. (Revised January 2013.)  View Details
    CiteView DetailsPurchase Related
  34. Supplement | HBS Case Collection | May 2012

    Westlake Lanes: How Can This Business Be Saved? Spreadsheet for Instructors (Brief Case)

    Richard G. Hamermesh and Alisa Zalosh

    Citation:

    Hamermesh, Richard G., and Alisa Zalosh. "Westlake Lanes: How Can This Business Be Saved? Spreadsheet for Instructors (Brief Case)." Harvard Business School Spreadsheet Supplement 124-434, May 2012.  View Details
    CiteView DetailsPurchase Related
  35. Supplement | HBS Case Collection | May 2012

    Westlake Lanes: How Can This Business Be Saved? Spreadsheet for Students (Brief Case)

    Richard G. Hamermesh and Alisa Zalosh

    Citation:

    Hamermesh, Richard G., and Alisa Zalosh. "Westlake Lanes: How Can This Business Be Saved? Spreadsheet for Students (Brief Case)." Harvard Business School Spreadsheet Supplement 124-433, May 2012.  View Details
    CiteView DetailsPurchase Related
  36. Teaching Note | HBS Case Collection | May 2012

    Westlake Lanes: How Can This Business Be Saved? (Brief Case)

    Richard G. Hamermesh and Alisa Zalosh

    Citation:

    Hamermesh, Richard G., and Alisa Zalosh. "Westlake Lanes: How Can This Business Be Saved? (Brief Case)." Harvard Business School Teaching Note 124-432, May 2012.  View Details
    CiteView DetailsPurchase Related
  37. Supplement | HBS Case Collection | November 2012

    Sugar Bowl, Spreadsheet for Instructors (Brief Case) (CW)

    Richard G. Hamermesh and Alisa Zalosh

    Citation:

    Hamermesh, Richard G., and Alisa Zalosh. "Sugar Bowl, Spreadsheet for Instructors (Brief Case) (CW)." Harvard Business School Spreadsheet Supplement 913-540, November 2012.  View Details
    CiteView DetailsPurchase Related
  38. Supplement | HBS Case Collection | November 2012

    Sugar Bowl, Spreadsheet for Students (Brief Case) (CW)

    Richard G. Hamermesh and Alisa Zalosh

    Citation:

    Hamermesh, Richard G., and Alisa Zalosh. "Sugar Bowl, Spreadsheet for Students (Brief Case) (CW)." Harvard Business School Spreadsheet Supplement 913-539, November 2012.  View Details
    CiteView DetailsPurchase Related
  39. Teaching Note | HBS Case Collection | November 2012

    Sugar Bowl (Brief Case) (TN)

    Richard G. Hamermesh and Alisa Zalosh

    Citation:

    Hamermesh, Richard G., and Alisa Zalosh. "Sugar Bowl (Brief Case) (TN)." Harvard Business School Teaching Note 913-538, November 2012.  View Details
    CiteView DetailsPurchase Related
  40. Case | HBS Case Collection | November 2012

    Sugar Bowl

    Richard G. Hamermesh and Alisa Zalosh

    Shelby Givens, a recent business school graduate, returned home to Raleigh, North Carolina, to help rescue her family's ailing and outdated bowling alley, Westlake Lanes. Although she cut costs and addressed inefficiencies, moving the business from near-bankruptcy to profitability in nine months, market conditions threatened the long-term viability of the business. Givens then sold her family on a new, more youth-oriented concept, an urban lounge called Sugar Bowl that could generate sizable revenues from the food and beverage businesses already embedded in Westlake Lanes. The case follows Givens as she builds Sugar Bowl into a turnaround story through shrewd decision making in finance, operations, and marketing, while contending constantly with challenging surprises and disappointments. The case also captures Givens's reflections on how the entrepreneurial drive has motivated her. Sugar Bowl may be taught alone or after "Westlake Lanes" (4431), which follows Givens through the initial turnaround process.

    Keywords: Family Business; Entrepreneurship; Operations; Performance; Business Strategy; Corporate Finance; Entertainment and Recreation Industry; Raleigh;

    Citation:

    Hamermesh, Richard G., and Alisa Zalosh. "Sugar Bowl." Harvard Business School Brief Case 913-537, November 2012.  View Details
    CiteView DetailsEducatorsPurchase Related
  41. Teaching Note | HBS Case Collection | December 2012

    Gene Patents (A) (TN)

    Richard G. Hamermesh and Matthew Preble

    This is the teaching note for case Gene Patents (A). In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.

    Keywords: patents; genetics; biotech; Human Genome; Patents; Genetics; Biotechnology Industry; United States;

    Citation:

    Hamermesh, Richard G., and Matthew Preble. "Gene Patents (A) (TN)." Harvard Business School Teaching Note 813-099, December 2012.  View Details
    CiteView DetailsPurchase Related
  42. Case | HBS Case Collection | November 2012 (Revised January 2013)

    Companion Diagnostics: Uncertainties for Approval and Reimbursement

    Richard G. Hamermesh, Norman C. Selby and Phillip Andrews

    The FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine. The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory practices at the agency. Beyond the regulatory questions, many considered the reimbursement system archaic, dispersed, unpredictable, and unnecessarily time consuming. Many questioned whether the traditional models of reimbursement were relevant in the era of personalized medicine, and who should be covering the cost of tests needed to identify the sometimes small number of patients who could benefit from expensive targeted drugs. This case focuses on the array of possibilities and the ambiguity surrounding these regulatory and reimbursement issues.

    Keywords: models of reimbursement; personalized medicine; regulation; healthcare reform; Health Care and Treatment; Health Industry; United States;

    Citation:

    Hamermesh, Richard G., Norman C. Selby, and Phillip Andrews. "Companion Diagnostics: Uncertainties for Approval and Reimbursement." Harvard Business School Case 813-037, November 2012. (Revised January 2013.)  View Details
    CiteView DetailsEducatorsPurchase Related
  43. Supplement | HBS Case Collection | November 2012

    Amylin Pharmaceuticals (B)

    Richard G. Hamermesh and Carin-Isabel Knoop

    Amylin Pharmaceuticals brought two first-in-class diabetes drugs to market, Byetta and Symlin, in 2005, which were sold in over 80 countries with $650.7 million in sales by 2011. However, the company remained unprofitable as sales plateaued. The small pharmaceutical company was hurt by long delays in bringing Bydureon, a once-a-week version of Byetta, to market, which allowed a competitor time to establish itself in the once-a-week market. Amylin also failed to develop a marketable anti-obesity drug after the purchase of the promising leptin molecule from Amgen, Inc. In 2012, Amylin was acquired by Bristol-Myers Squibb for $5.3 billion.

    Keywords: Pharmaceuticals; Bristol-Myers Squibb; Health Care and Treatment; Pharmaceutical Industry; United States;

    Citation:

    Hamermesh, Richard G., and Carin-Isabel Knoop. "Amylin Pharmaceuticals (B)." Harvard Business School Supplement 813-091, November 2012.  View Details
    CiteView DetailsPurchase Related
  44. Case | HBS Case Collection | May 2012

    Westlake Lanes: How Can This Business Be Saved?

    Richard G. Hamermesh and Alisa Zalosh

    Shelby Givens, a new MBA, is the general manager of Westlake Lanes, a near-bankrupt bowling alley that her grandfather founded decades earlier. Givens has been given one year to turn a profit; if the goal is not met Westlake will close. During the first few days on the job, Givens learns that the business is in worse shape financially than she—or the board—thought. She also finds that Westlake's employees exhibit minimal productivity. Givens tackles these two issues, creatively uncovering ways to reduce costs while building morale. After nine months, the business has its first profitable month in over two years. Yet Givens is worried it is too little, too late and begins to sketch a bolder long-term strategy based on pursuing one of two alternative new markets. Students are invited to consider whether the board should accept her potentially transformative proposal, maintain existing operations, or liquidate to pay off pressing loan responsibilities. The case includes a quantitative assignment for students.

    Keywords: United States; operations management; small and medium-sized enterprises; turnarounds; marketing strategy; entrepreneurship; strategy; Leading Change; Marketing Strategy; Entrepreneurship; Operations; Transformation; Growth and Development Strategy; Entertainment and Recreation Industry; United States;

    Citation:

    Hamermesh, Richard G., and Alisa Zalosh. "Westlake Lanes: How Can This Business Be Saved?" Harvard Business School Brief Case 124-431, May 2012.  View Details
    CiteView DetailsEducatorsPurchase Related
  45. Course Overview Note | September 2012 (Revised September 2012)

    Building Life Science Businesses Fall 2012: Course Outline and Syllabus

    Richard G. Hamermesh and Richard G. Hamermesh

    This Course Outline and Syllabus gives an overview of the Fall 2012 class Building Life Science Businesses

    Keywords: healthcare ventures; entrepreneurial management; entrepreneurship; entrepreneurs; Health Care and Treatment; Health Testing and Trials; Medical Specialties; Health Industry; Biotechnology Industry; Medical Devices and Supplies Industry; Asia; North America; Europe;

    Citation:

    Hamermesh, Richard G. "Building Life Science Businesses Fall 2012: Course Outline and Syllabus." Harvard Business School Course Overview Note 812-167, September 2012. (Revised from original June 2012 version.)  View Details
    CiteView Details Related
  46. Supplement | HBS Case Collection | April 2012

    Meli Marine, Spreadsheet Supplement (Brief Case)

    Richard G. Hamermesh and Sunru Yong

    Keywords: Asia; Singapore; industry structure; operations management; capacity analysis; supply chain management; competitive strategy; Logistics; packaging cartons &containers; Supply Chain Management; Competitive Strategy; Logistics; Industry Structures; Performance Capacity; Singapore;

    Citation:

    Hamermesh, Richard G., and Sunru Yong. "Meli Marine, Spreadsheet Supplement (Brief Case)." Harvard Business School Spreadsheet Supplement 124-429, April 2012.  View Details
    CiteView DetailsPurchase Related
  47. Supplement | HBS Case Collection | April 2012

    Meli Marine, Instructor Supplement (Brief Case)

    Richard G. Hamermesh and Sunru Yong

    Keywords: Asia; Singapore; industry structure; operations management; capacity analysis; supply chain management; competitive strategy; Logistics; packaging cartons &containers; Supply Chain Management; Competitive Strategy; Logistics; Industry Structures; Performance Capacity; Singapore;

    Citation:

    Hamermesh, Richard G., and Sunru Yong. "Meli Marine, Instructor Supplement (Brief Case)." Harvard Business School Spreadsheet Supplement 124-430, April 2012.  View Details
    CiteView DetailsPurchase Related
  48. Teaching Note | HBS Case Collection | April 2012

    Meli Marine (Brief Case)

    Richard G. Hamermesh and Sunru Yong

    Citation:

    Hamermesh, Richard G., and Sunru Yong. "Meli Marine (Brief Case)." Harvard Business School Teaching Note 124-427, April 2012.  View Details
    CiteView DetailsPurchase Related
  49. Case | HBS Case Collection | April 2012

    Meli Marine

    Richard G. Hamermesh and Sunru Yong

    Meli Marine, a container shipping company, is facing an important strategic decision after an interesting acquisition opportunity presents itself. Founded in 1974 by the Chang Family, the Singapore-based company has carved out a niche in the intra-Asia transport market. After years of success, eroding business conditions caused a financial crisis and a new CEO, David Tian, was brought in. Tian created a successful strategic change effort that resulted in a more stable but slower-growth company. More than ten years later, Meli Marine has a rare and affordable opportunity to acquire the larger shipping vessels it needs to move into a global market. Tian and his board must decide to whether to expand the franchise into Asian-North American shipping lanes, as key competitors have done, or continue with its current conservative business model.

    Citation:

    Hamermesh, Richard G., and Sunru Yong. "Meli Marine." Harvard Business School Brief Case 124-426, April 2012.  View Details
    CiteView DetailsEducatorsPurchase Related
  50. Supplement | HBS Case Collection | March 2012 (Revised October 2013)

    Gene Patents (B)

    Richard Hamermesh and Phillip Andrews

    The case updates events since the Court's ruling against Myriad Genetics on March 29, 2010 and should be used in conjunction with Gene Patents (A). On July 29, 2011, a US Appeals Court reversed the prior ruling against Myriad. On September 16, 2011, the first major overhaul of US Patent law in nearly 60 years was signed into law. Among other provisions, the law moved the US to a first-to-file priority when granting patents, as was the practice in most of the rest of the world. Many felt this change would help to reduce the amount of patent litigation. The case ends with the Supreme Court's 9 to 0 vote on March 29, 2012 ruling against another company in a case similar to Myriad's. Within five days of that decision, the Supreme Court remanded the Myriad case back down to the Court of Appeals for reconsideration.

    Keywords: Courts and Trials; Patents; Genetics; Judgments; Investment; Biotechnology Industry; United States;

    Citation:

    Hamermesh, Richard, and Phillip Andrews. "Gene Patents (B)." Harvard Business School Supplement 812-130, March 2012. (Revised October 2013.)  View Details
    CiteView DetailsPurchase Related
  51. Case | HBS Case Collection | June 2011 (Revised October 2013)

    Gene Patents (A)

    Richard Hamermesh, David Kiron and Phillip Andrews

    In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with the potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.

    Keywords: Courts and Trials; Patents; Genetics; Judgments; Science-Based Business; Biotechnology Industry; United States;

    Citation:

    Hamermesh, Richard, David Kiron, and Phillip Andrews. "Gene Patents (A)." Harvard Business School Case 811-089, June 2011. (Revised October 2013.)  View Details
    CiteView DetailsEducatorsPurchase Related
  52. Background Note | HBS Case Collection | November 2005 (Revised November 2011)

    Entrepreneurship and Venture Capital in Healthcare Fall Term 2011: Course Outline and Syllabus

    Richard G. Hamermesh and Robert F. Higgins

    Provides an overview of the second-year MBA elective course Entrepreneurship and Venture Capital in Healthcare.

    Keywords: Entrepreneurship; Venture Capital; Health Care and Treatment;

    Citation:

    Hamermesh, Richard G., and Robert F. Higgins. "Entrepreneurship and Venture Capital in Healthcare Fall Term 2011: Course Outline and Syllabus." Harvard Business School Background Note 806-048, November 2005. (Revised November 2011.)  View Details
    CiteView DetailsEducatorsPurchase Related
  53. Case | HBS Case Collection | October 2011 (Revised December 2012)

    eHealthpoint: Healthcare for Rural India

    Richard G. Hamermesh, Mona Sinha and Elizabeth Vrolyk

    Healthpoint Services sought to address rural India's shortage of quality and affordable healthcare with a multi-service platform that comprised telemedical health clinics called eHealthpoints, clean drinking water, a diagnostic lab, and a pharmacy. Could they convince rural Indians to leapfrog from local healers to telemedicine? And could they convince Investors that their capital Intensive, bundled offering was a high-growth, self-sustaining venture? Healthpoint Services grappled with multiple challenges: changing mind-sets of patients and investors, generating traffic at their eHealthpoints, expanding their product portfolio, and growing within and outside India.

    Keywords: Health Care and Treatment; Health Industry; India;

    Citation:

    Hamermesh, Richard G., Mona Sinha, and Elizabeth Vrolyk. "eHealthpoint: Healthcare for Rural India." Harvard Business School Case 812-020, October 2011. (Revised December 2012.)  View Details
    CiteView DetailsEducatorsPurchase Related
  54. Case | HBS Case Collection | October 2011

    Gene Sequencing: Staking a Position in an Expanding Industry

    Richard G. Hamermesh, Mara Aspinall and Phillip Andrews

    Towards the end of 2010, companies in the gene sequencing industry were pushing aggressive R&D programs to develop technologies and products in the race to sequence the entire human genome at a cost of $1,000. It remained to be seen when the "$1,000 genome" would arrive, and despite all of the buzz surrounding the industry, it was still unclear to investors who the industry winners would be. This case focuses on the emergence of third-generation sequencing and the four segments in the industry: hardware, consumables, services, and interpretation. The case presents the history of the industry, the evolution of sequencing technology, and the business models of players in each segment.

    Keywords: Genetics; Business Growth and Maturation; Business Plan; Competition; Venture Capital; Biotechnology Industry;

    Citation:

    Hamermesh, Richard G., Mara Aspinall, and Phillip Andrews. "Gene Sequencing: Staking a Position in an Expanding Industry." Harvard Business School Case 812-004, October 2011.  View Details
    CiteView DetailsFind at Harvard Related
  55. Background Note | HBS Case Collection | August 2011 (Revised September 2011)

    U.S. Universities and Technology Transfer

    Richard G. Hamermesh, Josh Lerner and Phillip Andrews

    Technology transfer from U.S. universities to industry has increased dramatically in the last 25 years. Reviews the history of technology transfer with particular emphasis on the Bayh-Dole Act of 1980. It then examines how universities responded to Bayh-Dole, the growth of technology transfer offices, and compares how three different universities (MIT, Stanford, and Harvard) approach technology transfer. Provides an overview of the technology transfer process and issues around current practices.

    Keywords: Higher Education; Technology; Laws and Statutes; Education Industry; Technology Industry; United States;

    Citation:

    Hamermesh, Richard G., Josh Lerner, and Phillip Andrews. "U.S. Universities and Technology Transfer." Harvard Business School Background Note 812-016, August 2011. (Revised September 2011.)  View Details
    CiteView DetailsEducatorsPurchase Related
  56. Case | HBS Case Collection | October 2010 (Revised July 2011)

    Primedic—Providing Primary Care in Mexico

    Richard G. Hamermesh, Regina Garcia-Cuellar and Lauren Sarah Margulies

    Primedic is a Mexican start-up that aims to deliver affordable primary and preventative healthcare to those at the base of the economic pyramid. The company is about to exhaust its first round of venture capital funding and the business model has yet to gain traction. How should the business model be changed and should the venture capitalists continue to fund the company?

    Keywords: Business Model; Business Startups; Developing Countries and Economies; Social Entrepreneurship; Venture Capital; Health Care and Treatment; Social Enterprise; Health Industry; Mexico;

    Citation:

    Hamermesh, Richard G., Regina Garcia-Cuellar, and Lauren Sarah Margulies. "Primedic—Providing Primary Care in Mexico." Harvard Business School Case 811-040, October 2010. (Revised July 2011.)  View Details
    CiteView DetailsEducatorsPurchase Related
  57. Teaching Note | HBS Case Collection | June 2011

    Whose Money Is It Anyway? (TN) (A), (B), and (C)

    Richard G. Hamermesh, V.G. Narayanan and Rachel Gordon

    Teaching Note for 810-008, 810-013, and 810-031.

    Keywords: Health Industry;

    Citation:

    Hamermesh, Richard G., V.G. Narayanan, and Rachel Gordon. "Whose Money Is It Anyway? (TN) (A), (B), and (C)." Harvard Business School Teaching Note 111-128, June 2011.  View Details
    CiteView Details Related
  58. Teaching Note | HBS Case Collection | June 2011

    Novasys Medical (TN)

    Richard G. Hamermesh

    Teaching Note for 810027.

    Keywords: Product Development; Health Care and Treatment; Policy; Medical Devices and Supplies Industry;

    Citation:

    Hamermesh, Richard G. "Novasys Medical (TN)." Harvard Business School Teaching Note 811-084, June 2011.  View Details
    CiteView DetailsPurchase Related
  59. Case | HBS Case Collection | March 2011 (Revised March 2011)

    Horizon Blue Cross Blue Shield of New Jersey - Managing in the Shadow of Health Care Reform

    Felix Oberholzer-Gee, Raffaella Sadun and Richard G. Hamermesh

    Per the Patient Protection and Affordable Care Act (PPACA), which President Obama signed in 2010, states would be required to create state-wide health insurance marketplaces - the Health Benefit Exchanges (HBEs) - in which individuals and small employers could choose from a set of easy-to-compare, tightly regulated health plans. This case explores how Horizon Blue Cross Blue Shield of New Jersey would have to decide whether and how to compete in New Jersey's HBEs.

    Keywords: Insurance; Health Care and Treatment; Governing Rules, Regulations, and Reforms; Emerging Markets; Risk and Uncertainty; Health Industry; Insurance Industry; New Jersey;

    Citation:

    Oberholzer-Gee, Felix, Raffaella Sadun, and Richard G. Hamermesh. "Horizon Blue Cross Blue Shield of New Jersey - Managing in the Shadow of Health Care Reform." Harvard Business School Case 711-403, March 2011. (Revised March 2011.)  View Details
    CiteView DetailsEducatorsPurchase Related
  60. Teaching Note | HBS Case Collection | March 2011

    Primedic—Providing Primary Care in Mexico (TN)

    Richard G. Hamermesh

    Teaching Note for 811040.

    Keywords: Business Startups; Health Care and Treatment; Venture Capital; Financing and Loans; Business Model; Medical Devices and Supplies Industry; Mexico;

    Citation:

    Hamermesh, Richard G. "Primedic—Providing Primary Care in Mexico (TN)." Harvard Business School Teaching Note 811-074, March 2011.  View Details
    CiteView DetailsPurchase Related
  61. Case | HBS Case Collection | November 2010 (Revised January 2011)

    Computerized Provider Order Entry at Emory Healthcare

    Richard G. Hamermesh, F. Warren McFarlan, Mark Keil, Andrew Katz, Michael Morgan and David LaBorde

    The Computerized Provider Order Entry at Emory Healthcare case presents one hospital system's efforts to implement computerized provider order entry (CPOE) across all of its hospitals and the challenges they faced in doing so. Issues such as standardization of care, how to handle medication reconciliation, and unexpected challenges (e.g., changes to the post-op ordering process, lack of a human gatekeeper to monitor order flow, increase in lab orders). Dr. Bill Bornstein, Chief Quality and Medical Officer of Emory Healthcare in Atlanta is responsible for the smooth implementation of CPOE at Emory Healthcare, which is a vital part of their $50 million electronic medical record initiative. By June 2009, CPOE had gone "live" at Emory University Orthopaedics and Spine Hospital, Emory University Hospital, and Wesley Woods Hospital in a staged rollout. While Dr. Bornstein felt good about how the implementation had gone thus far, as he looked ahead next month to July 13, 2009, the fast approaching go-live date for Emory University Hospital Midtown (EUHM), he was concerned about the challenges and possible perils that lay ahead. He considered what additional actions he should take to prepare for go-live at Midtown, and if Midtown was ready for CPOE at all. One thing was certain; this hospital was different. The Computerized Provider Order Entry at Emory Healthcare case presents one hospital system's efforts to grapple with the challenges of implementing CPOE and the reactions that result. Issues such as how to deal with a workforce that has mixed views about the value of implementing such systems, the pros and cons associated with standardization of care, as well as how to deal with unexpected changes to work processes are brought out in the case. The case also allows for discussion of how to plan a phased implementation with adequate time for organizational learning to occur between the time that various sites "go live."

    Keywords: Health Care and Treatment; Information Management; Management Systems; Standards; Service Delivery; Business Processes; Organizational Change and Adaptation; Projects; Information Technology; Software; Health Industry;

    Citation:

    Hamermesh, Richard G., F. Warren McFarlan, Mark Keil, Andrew Katz, Michael Morgan, and David LaBorde. "Computerized Provider Order Entry at Emory Healthcare." Harvard Business School Case 311-061, November 2010. (Revised January 2011.)  View Details
    CiteView DetailsEducatorsPurchase Related
  62. Background Note | HBS Case Collection | January 2001 (Revised January 2011)

    The Entrepreneurial Manager 2011 Winter Term: Course Overview

    Richard G. Hamermesh

    Course overview of The Entrepreneurial Manager.

    Keywords: Entrepreneurship; Management; Business Education;

    Citation:

    Hamermesh, Richard G. "The Entrepreneurial Manager 2011 Winter Term: Course Overview." Harvard Business School Background Note 801-325, January 2001. (Revised January 2011.)  View Details
    CiteView DetailsFind at Harvard Related
  63. Background Note | HBS Case Collection | October 2010 (Revised November 2010)

    Plavix: Drugs in the Age of Personalized Medicine

    Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon

    PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even death if they took PIavix. As a result, the FDA had added a black box warning—the agency's most severe—to Plavix's label in 2010. In addition, it had been discovered that the common combination of Plavix and Prilosec, an over-the-counter drug, could adversely affect patients. Finally, Plavix faced new competition from two new drugs with different mechanisms of action. This case reviews the recent history of Plavix in greater detail to encourage a discussion of the following questions: How might the current manufacturers of Plavix handle these emerging threats to their leading blockbuster? How might Plavix's potential competitors utilize Plavix's mixed history to their advantage? How should genotyping be integrated into the clinical care of patients in the light of emerging knowledge?

    Keywords: Health Care and Treatment; Product Positioning; Business and Government Relations; Genetics; Competitive Strategy; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., Mara G. Aspinall, and Rachel Gordon. "Plavix: Drugs in the Age of Personalized Medicine." Harvard Business School Background Note 811-001, October 2010. (Revised November 2010.)  View Details
    CiteView DetailsEducatorsPurchase Related
  64. Case | HBS Case Collection | September 2007 (Revised October 2010)

    DermaCare: Zapping Zits Directly

    Richard G. Hamermesh and Lauren Barley

    DermaCare has developed an innovative new product for the treatment of acne that they hope to sell to consumers via direct-response television. The unconventional nature of the product and its distribution has led the company to seek angel financing. The Silicon Valley Band of Angels has agreed to finance the company and has submitted a proposed term sheet. Recently, however, a venture capital (VC) group has submitted a competing term sheet. The company must decide whether to accept financing from the Angels or the VC group.

    Keywords: Decision Choices and Conditions; Venture Capital; Investment; Innovation and Invention; Product; California;

    Citation:

    Hamermesh, Richard G., and Lauren Barley. "DermaCare: Zapping Zits Directly." Harvard Business School Case 808-064, September 2007. (Revised October 2010.)  View Details
    CiteView DetailsEducatorsPurchase Related
  65. Teaching Note | HBS Case Collection | October 2010 (Revised June 2015)

    MINTing Innovation at NewYork-Presbyterian (A) and (B)

    Richard G. Hamermesh and David Kiron

    Teaching Note for 810004 and 815113.

    Keywords: Commercialization; Technological Innovation; Health Industry;

    Citation:

    Hamermesh, Richard G., and David Kiron. "MINTing Innovation at NewYork-Presbyterian (A) and (B)." Harvard Business School Teaching Note 811-010, October 2010. (Revised June 2015.)  View Details
    CiteView DetailsPurchase Related
  66. Case | HBS Case Collection | May 2009 (Revised August 2010)

    The Jenner Situation

    Richard G. Hamermesh, Andy Whittemore and Eliot Sherman

    Dr. Bill Lemont is the new chief medical officer of a large academic medical center. During his first week on the job he has become aware of the abusive behavior and temper outbursts of a prominent orthopedic surgeon. How Dr. Lemont handles the situation will be scrutinized inside and perhaps outside the hospital.

    Keywords: Interpersonal Communication; Employee Relationship Management; Managerial Roles; Behavior; Conflict Management; Health Industry;

    Citation:

    Hamermesh, Richard G., Andy Whittemore, and Eliot Sherman. "The Jenner Situation." Harvard Business School Case 809-070, May 2009. (Revised August 2010.)  View Details
    CiteView DetailsEducatorsPurchase Related
  67. Case | HBS Case Collection | March 2010 (Revised June 2010)

    Whose Money Is It Anyway? (A)

    V.G. Narayanan, Richard G. Hamermesh and Rachel Gordon

    The Brigham and Women's Physician's Organization (BWPO) and its corporate parent disagree over who has jurisdiction over significant legacy funds. Are they controlled by the BWPO or do they belong to BWPO's corporate parent? The BWPO and its corporate parent must negotiate who has control of the funds which impacts how the funds may be used.

    Keywords: Accounting; Investment Funds; Governance Controls; Agreements and Arrangements; Boundaries; Health Industry;

    Citation:

    Narayanan, V.G., Richard G. Hamermesh, and Rachel Gordon. "Whose Money Is It Anyway? (A)." Harvard Business School Case 810-008, March 2010. (Revised June 2010.)  View Details
    CiteView DetailsEducatorsPurchase Related
  68. Teaching Note | HBS Case Collection | November 2004 (Revised May 2010)

    Shurgard Self-Storage: Expansion to Europe and Shurgard Self-Storage: Expansion to Europe (Abridged) (TN)

    Richard G. Hamermesh and Indra Reinbergs

    Keywords: Europe;

    Citation:

    Hamermesh, Richard G., and Indra Reinbergs. "Shurgard Self-Storage: Expansion to Europe and Shurgard Self-Storage: Expansion to Europe (Abridged) (TN)." Harvard Business School Teaching Note 805-080, November 2004. (Revised May 2010.)  View Details
    CiteView DetailsPurchase Related
  69. Case | HBS Case Collection | December 2008 (Revised April 2010)

    Proteus Biomedical: Making Pigs Fly

    Richard G. Hamermesh, Lauren Barley and Ginger Graham

    Proteus is a healthcare start-up that has developed technology to embed electronics for computing and sensing in existing medical devices and drugs. The technology could potentially change the basis of competition in the pharmaceutical industry. The company is currently considering a number of licensing and business development deals and must choose which one(s) to pursue.

    Keywords: Business Startups; Entrepreneurship; Technological Innovation; Rights; Negotiation Deal; Business Strategy; Health Industry; Medical Devices and Supplies Industry; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., Lauren Barley, and Ginger Graham. "Proteus Biomedical: Making Pigs Fly." Harvard Business School Case 809-051, December 2008. (Revised April 2010.)  View Details
    CiteView DetailsEducatorsPurchase Related
  70. Case | HBS Case Collection | November 2009 (Revised March 2010)

    Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story

    Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon

    In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had received approval several years prior. Moreover, Vectibix had also received Food and Drug Administration approval in 2006. During additional trials, Amgen has learned that the Vectibix is only effective with the 60% of the population that has a specific gene marker. Given this development, what should Amgen's strategy around Vectibix be both in Europe and the United States?

    Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States;

    Citation:

    Hamermesh, Richard G., Raju Kucherlapati, and Rachel Gordon. "Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story." Harvard Business School Case 810-066, November 2009. (Revised March 2010.)  View Details
    CiteView DetailsEducatorsPurchase Related
  71. Supplement | HBS Case Collection | March 2010

    Whose Money Is It Anyway? (B)

    V.G. Narayanan, Richard G. Hamermesh and Rachel Gordon

    The case describes the various reactions of doctors and administrators to the solutions they developed.

    Keywords: Corporate Governance; Organizations; Behavior; Health Industry;

    Citation:

    Narayanan, V.G., Richard G. Hamermesh, and Rachel Gordon. "Whose Money Is It Anyway? (B)." Harvard Business School Supplement 810-013, March 2010.  View Details
    CiteView DetailsPurchase Related
  72. Supplement | HBS Case Collection | March 2010

    Whose Money Is It Anyway? (C)

    V.G. Narayanan, Richard G. Hamermesh and Rachel Gordon

    The case describes how the Brigham and Women's Physicians Organization and its corporate parent resolved the issue of how the disputed funds would be distributed and used.

    Keywords: Corporate Governance; Business Subsidiaries; Organizational Design; Conflict and Resolution; Resource Allocation; Health Industry;

    Citation:

    Narayanan, V.G., Richard G. Hamermesh, and Rachel Gordon. "Whose Money Is It Anyway? (C)." Harvard Business School Supplement 810-031, March 2010.  View Details
    CiteView DetailsPurchase Related
  73. Case | HBS Case Collection | December 2008 (Revised October 2013)

    Amylin Pharmaceuticals: Diabetes and Beyond (A)

    Richard G. Hamermesh and Rachel Gordon

    Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a second drug, Byetta, in its pipeline. Graham must decide how to manage the company's limited resources while also finalizing another deal that has huge future potential. Graham knows that Amylin's immediate success depends on its ability to commercialize its products, but its long-term success depends on replenishing its pipeline. Can the company do it all successfully?

    Keywords: regulations; drug regulations; Symlin; negotiation; Governing Rules, Regulations, and Reforms; Resource Allocation; Negotiation Deal; Product Development; Research and Development; Commercialization; Pharmaceutical Industry; United States;

    Citation:

    Hamermesh, Richard G., and Rachel Gordon. "Amylin Pharmaceuticals: Diabetes and Beyond (A)." Harvard Business School Case 809-011, December 2008. (Revised October 2013.)  View Details
    CiteView DetailsEducatorsPurchase Related
  74. Case | HBS Case Collection | February 2010

    Shurgard Self-Storage: Expansion to Europe (Abridged)

    Richard G. Hamermesh

    Shurgard, a U.S.-based firm that rents storage facilities to consumers and small businesses, is considering financing options for rapid expansion of its European operations. Five years after entering Europe, Shurgard Europe has opened 17 facilities in Belgium, France, and Sweden. Along the way, Shurgard has encountered skepticism from both European consumers and investors about the unfamiliar self-storage concept and internal debates on how much to adapt the U.S. business model to European lifestyles. Wall Street analysts also do not value the impact that the European expansion could have on Shurgard's U.S. performance as a publicly traded Real Estate Investment Trust (REIT). As an alternative, to finance this expansion, Shurgard received a proposed deal from a consortium of banks and other investors where they would provide private equity financing spaced over the next few years plus a line of credit. In return, the investors would receive a large share of Shurgard's equity and control of its board, which could force a public offering in less than two years. The decision focuses on whether Shurgard Europe should accept the conditions and valuation of the proposed deal or seek another deal at a later point in time. Students must assess whether the self-storage business model can deliver the growth rate in Europe that the company has promised its potential investors. Involves calculating some basic estimates of the company's value from financial exhibits (enterprise value using an EBITDA multiple). Main focus is to assess this as an entrepreneurial venture. Students do not need to be familiar with REITs.

    Keywords: Business Model; Business Growth and Maturation; Multinational Firms and Management; Logistics; Corporate Entrepreneurship; Trade; Equity; Corporate Finance; United States; Europe;

    Citation:

    Hamermesh, Richard G. "Shurgard Self-Storage: Expansion to Europe (Abridged)." Harvard Business School Case 810-102, February 2010.  View Details
    CiteView DetailsEducatorsPurchase Related
  75. Teaching Note | HBS Case Collection | January 2010

    State of Emergency at Mercy Hospital and The Jenner Situation (TN)

    Richard G. Hamermesh

    Teaching Note for [809070] and [409048].

    Keywords: Health; Non-Governmental Organizations; Health Industry;

    Citation:

    Hamermesh, Richard G. "State of Emergency at Mercy Hospital and The Jenner Situation (TN)." Harvard Business School Teaching Note 810-068, January 2010.  View Details
    CiteView DetailsPurchase Related
  76. Case | HBS Case Collection | August 2009 (Revised June 2015)

    MINTing Innovation at NewYork-Presbyterian (A)

    Richard G. Hamermesh and David Kiron

    Several top surgeons at NewYork-Presbyterian Hospital (NYP) are receiving financial and administrative support to advance their surgical device inventions through the earliest stages of commercialization.

    Keywords: health care; innovation & entrepreneurship; hospital; Entrepreneurship; Financing and Loans; Investment; Health Care and Treatment; Innovation and Invention; Intellectual Property; Commercialization; Health Industry; Medical Devices and Supplies Industry; New York (state, US);

    Citation:

    Hamermesh, Richard G., and David Kiron. "MINTing Innovation at NewYork-Presbyterian (A)." Harvard Business School Case 810-004, August 2009. (Revised June 2015.)  View Details
    CiteView DetailsEducatorsPurchase Related
  77. Teaching Note | HBS Case Collection | February 2008 (Revised January 2010)

    Calloway Laboratory: Pee for Profit (TN)

    Richard G. Hamermesh

    Teaching Note for [807-040].

    Keywords: Profit;

    Citation:

    Hamermesh, Richard G. "Calloway Laboratory: Pee for Profit (TN)." Harvard Business School Teaching Note 808-119, February 2008. (Revised January 2010.)  View Details
    CiteView DetailsPurchase Related
  78. Case | HBS Case Collection | November 2009

    The Explosion of Genetic Testing: Opportunities and Challenges

    Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon

    This case study invites the reader to consider genetic testing in several different lights. First, can the business of genetic testing be considered a disruptive innovation to the current drug therapy model as defined by Harvard Business School Professor Clay Christensen? Secondly, which business models are likely to be the most successful? Finally, we encourage readers to explore possible future business implications and applications in the area of genetic testing while using a framework of disruptive innovation.

    Keywords: Genetics; Health Care and Treatment; Health Testing and Trials; Disruptive Innovation; Business Model; Biotechnology Industry; Health Industry;

    Citation:

    Hamermesh, Richard G., Mara G. Aspinall, and Rachel Gordon. "The Explosion of Genetic Testing: Opportunities and Challenges." Harvard Business School Case 810-067, November 2009.  View Details
    CiteView DetailsEducators Related
  79. Case | HBS Case Collection | September 2007 (Revised May 2009)

    Syndexa and Technology Transfer at Harvard University

    Richard G. Hamermesh and David Kiron

    Gokhan Hotamisligil is a star researcher at Harvard School of Public Health who has made groundbreaking discoveries linking fat cells, inflammation, and diabetes. He now wants to form a company to commercialize these discoveries. At the same time, Isaac Kohlberg, the head of Harvard's Office of Technology Development (OTD), is eager to improve Harvard's record in commercializing science. Describes the negotiations between Hotamisligil, OTD, the new company, and the School of Public Health to establish appropriate licensing and sponsored research agreements.

    Keywords: Business Startups; Higher Education; Entrepreneurship; Innovation and Invention; Intellectual Property; Rights; Agreements and Arrangements; Science-Based Business; Commercialization; Biotechnology Industry; Health Industry;

    Citation:

    Hamermesh, Richard G., and David Kiron. "Syndexa and Technology Transfer at Harvard University." Harvard Business School Case 808-073, September 2007. (Revised May 2009.)  View Details
    CiteView DetailsEducatorsPurchase Related
  80. Teaching Note | HBS Case Collection | April 2009

    Amylin Pharmaceuticals: Diabetes and Beyond (TN)

    Richard G. Hamermesh and Rachel Gordon

    Teaching Note for [809011].

    Keywords: Negotiation Deal; Product Development; Success; Commercialization; Governing Rules, Regulations, and Reforms; Resource Allocation; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., and Rachel Gordon. "Amylin Pharmaceuticals: Diabetes and Beyond (TN)." Harvard Business School Teaching Note 809-127, April 2009.  View Details
    CiteView DetailsPurchase Related
  81. Teaching Note | HBS Case Collection | March 2009

    Proteus Biomedical: Making Pigs Fly (TN)

    Richard G. Hamermesh

    Teaching Note for [809051].

    Keywords: Business Startups; Technology; Competition; Negotiation Deal; Health Industry; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G. "Proteus Biomedical: Making Pigs Fly (TN)." Harvard Business School Teaching Note 809-128, March 2009.  View Details
    CiteView DetailsPurchase Related
  82. Teaching Note | HBS Case Collection | February 2009

    Technology Transfer at U.S. Universities (TN)

    Richard G. Hamermesh

    Teaching Note for [807124].

    Keywords: United States;

    Citation:

    Hamermesh, Richard G. "Technology Transfer at U.S. Universities (TN)." Harvard Business School Teaching Note 809-106, February 2009.  View Details
    CiteView DetailsPurchase Related
  83. Teaching Note | HBS Case Collection | February 2009

    Syndexa and Technology Transfer at Harvard University (TN)

    Richard G. Hamermesh

    Teaching Note for [808073].

    Keywords: Agreements and Arrangements; Commercialization; Science-Based Business; Research; Rights; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G. "Syndexa and Technology Transfer at Harvard University (TN)." Harvard Business School Teaching Note 809-107, February 2009.  View Details
    CiteView DetailsPurchase Related
  84. Teaching Note | HBS Case Collection | March 2006 (Revised February 2009)

    Molecular Insight Pharmaceuticals, Inc. (TN)

    Richard G. Hamermesh and Erin Seefeld

    Teaching Note to (805-067).

    Keywords: Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., and Erin Seefeld. "Molecular Insight Pharmaceuticals, Inc. (TN)." Harvard Business School Teaching Note 806-140, March 2006. (Revised February 2009.)  View Details
    CiteView DetailsPurchase Related
  85. Teaching Note | HBS Case Collection | January 2008 (Revised January 2009)

    Cynthia Fisher and the Rearing of ViaCell (TN)

    Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld

    Teaching Note for [806002].

    Keywords: Management;

    Citation:

    Higgins, Robert F., Richard G. Hamermesh, and Erin Seefeld. "Cynthia Fisher and the Rearing of ViaCell (TN)." Harvard Business School Teaching Note 808-115, January 2008. (Revised January 2009.)  View Details
    CiteView DetailsPurchase Related
  86. Case | HBS Case Collection | March 2008 (Revised June 2008)

    Healthcare and Harvard Business School Alumni in 2008

    Richard G. Hamermesh, Carin-Isabel Knoop and Cara Sterling

    This case chronicles the role that Harvard Business School alumni play in the healthcare industry. Overall data on alumni is given, and the industry is broken into seven areas in which the careers of twenty-five alumni are highlighted.

    Keywords: Business Education; Executive Education; Personal Development and Career; Practice; Health Industry;

    Citation:

    Hamermesh, Richard G., Carin-Isabel Knoop, and Cara Sterling. "Healthcare and Harvard Business School Alumni in 2008." Harvard Business School Case 808-044, March 2008. (Revised June 2008.)  View Details
    CiteView DetailsEducatorsPurchase Related
  87. Supplement | HBS Case Collection | April 2008

    ProfitLogic (CW)

    Lynda M. Applegate, Richard G. Hamermesh and Michael J. Roberts

    This interactive spreadsheet accompanies the ProfitLogic case (#802-110) to enable analysis of the cash flow implications of three business models that the company is considering. Students are able to change key assumptions and see the impact on cash flow.

    Keywords: Cash Flow; Business Model;

    Citation:

    Applegate, Lynda M., Richard G. Hamermesh, and Michael J. Roberts. "ProfitLogic (CW)." Harvard Business School Spreadsheet Supplement 808-704, April 2008.  View Details
    CiteView DetailsPurchase Related
  88. Teaching Note | HBS Case Collection | February 2008

    DermaCare: Zapping Zits Directly (TN)

    Richard G. Hamermesh

    Teaching Note for [808064].

    Keywords: Product Development; Innovation and Invention; Health Care and Treatment; Financing and Loans; Venture Capital; Advertising; Distribution; Health Industry;

    Citation:

    Hamermesh, Richard G. "DermaCare: Zapping Zits Directly (TN)." Harvard Business School Teaching Note 808-122, February 2008.  View Details
    CiteView DetailsPurchase Related
  89. Case | HBS Case Collection | December 2005 (Revised October 2013)

    Fred Khosravi and AccessClosure (A)

    Richard Hamermesh and Liz Kind

    Fred Khosravi is a serial medical device entrepreneur. In his latest venture, he must decide whether to sell now or continue to develop his current product and whether to market it, sell the company, or IPO.

    Keywords: negotiation; medical devices; venture capital; life sciences; health care industry; Healthcare Technology; healthcare ventures; Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Medical Devices and Supplies Industry; United States;

    Citation:

    Hamermesh, Richard, and Liz Kind. "Fred Khosravi and AccessClosure (A)." Harvard Business School Case 806-044, December 2005. (Revised October 2013.)  View Details
    CiteView DetailsEducatorsPurchase Related
  90. Case | HBS Case Collection | October 2006 (Revised August 2007)

    Calloway Laboratory: Pee for Profit

    Richard G. Hamermesh and David Kiron

    Describes the formation and rapid growth of a drug-testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business.

    Keywords: For-Profit Firms; Health Care and Treatment; Health Testing and Trials; Growth and Development Strategy; Market Entry and Exit; Health Industry;

    Citation:

    Hamermesh, Richard G., and David Kiron. "Calloway Laboratory: Pee for Profit." Harvard Business School Case 807-040, October 2006. (Revised August 2007.)  View Details
    CiteView DetailsEducatorsPurchase Related
  91. Case | HBS Case Collection | February 2006 (Revised July 2007)

    Corporate Venture Capital at Eli Lilly

    Richard G. Hamermesh, Ron Laufer and David Lane

    Reviews the role of corporate venture capital and its history at Eli Lilly. Also presents a challenging venture investment opportunity.

    Keywords: Venture Capital; Investment; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., Ron Laufer, and David Lane. "Corporate Venture Capital at Eli Lilly." Harvard Business School Case 806-092, February 2006. (Revised July 2007.)  View Details
    CiteView DetailsEducatorsPurchase Related
  92. Background Note | HBS Case Collection | January 2007 (Revised June 2007)

    Technology Transfer at U.S. Universities

    Richard G. Hamermesh, Josh Lerner and David Kiron

    Technology transfer from U.S. universities to industry has increased dramatically in the last 25 years. Reviews the history of technology transfer with particular emphasis on the Bayh-Dole Act of 1980. It then examines how universities responded to Bayh-Dole, the growth of technology transfer offices, and compares how three different universities (MIT, Stanford, and Harvard) approach technology transfer. Provides an overview of the technology transfer process and issues around current practices.

    Keywords: Higher Education; Technology; Laws and Statutes; Education Industry; Technology Industry; United States;

    Citation:

    Hamermesh, Richard G., Josh Lerner, and David Kiron. "Technology Transfer at U.S. Universities." Harvard Business School Background Note 807-124, January 2007. (Revised June 2007.)  View Details
    CiteView DetailsEducatorsPurchase Related
  93. Teaching Note | HBS Case Collection | June 2007

    Endo Pharmaceuticals Series (TN)

    Richard G. Hamermesh, Brian DeLacey and Erin Seefeld

    Keywords: Information;

    Citation:

    Hamermesh, Richard G., Brian DeLacey, and Erin Seefeld. "Endo Pharmaceuticals Series (TN)." Harvard Business School Teaching Note 807-166, June 2007.  View Details
    CiteView DetailsPurchase Related
  94. Teaching Note | HBS Case Collection | May 2007

    DentalCorp (TN)

    Richard G. Hamermesh and Erin Seefeld

    Keywords: Health; Health Industry;

    Citation:

    Hamermesh, Richard G., and Erin Seefeld. "DentalCorp (TN)." Harvard Business School Teaching Note 807-163, May 2007.  View Details
    CiteView DetailsPurchase Related
  95. Case | HBS Case Collection | January 2006 (Revised May 2007)

    Endo Pharmaceuticals (A): From LBO to...?

    Richard G. Hamermesh and Brian DeLacey

    Endo Pharmaceuticals was formed in 1997 as a leveraged buyout spin-off from DuPont Merck. In 1999, it must decide whether to do an IPO or merge with a smaller company.

    Keywords: Private Equity; Initial Public Offering; Leveraged Buyouts; Mergers and Acquisitions; Health Care and Treatment; Pharmaceutical Industry; United States;

    Citation:

    Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (A): From LBO to...?" Harvard Business School Case 806-064, January 2006. (Revised May 2007.)  View Details
    CiteView DetailsEducatorsPurchase Related
  96. Supplement | HBS Case Collection | January 2006 (Revised May 2007)

    Endo Pharmaceuticals (B): Merger Decision

    Richard G. Hamermesh and Brian DeLacey

    Keywords: Mergers and Acquisitions; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (B): Merger Decision." Harvard Business School Supplement 806-065, January 2006. (Revised May 2007.)  View Details
    CiteView DetailsPurchase Related
  97. Supplement | HBS Case Collection | January 2006 (Revised May 2007)

    Endo Pharmaceuticals (C): An "At Risk" Launch?

    Richard G. Hamermesh and Brian DeLacey

    Keywords: Product Launch; Risk and Uncertainty; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., and Brian DeLacey. Endo Pharmaceuticals (C): An "At Risk" Launch? Harvard Business School Supplement 806-066, January 2006. (Revised May 2007.)  View Details
    CiteView DetailsPurchase Related
  98. Supplement | HBS Case Collection | January 2006 (Revised May 2007)

    Endo Pharmaceuticals (D): Hatch-Waxman Change

    Richard G. Hamermesh and Brian DeLacey

    Keywords: Change; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (D): Hatch-Waxman Change." Harvard Business School Supplement 806-067, January 2006. (Revised May 2007.)  View Details
    CiteView DetailsPurchase Related
  99. Supplement | HBS Case Collection | January 2006 (Revised May 2007)

    Endo Pharmaceuticals (E): Judge Stein Rules

    Richard G. Hamermesh and Brian DeLacey

    Keywords: Lawsuits and Litigation; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (E): Judge Stein Rules." Harvard Business School Supplement 806-081, January 2006. (Revised May 2007.)  View Details
    CiteView DetailsPurchase Related
  100. Supplement | HBS Case Collection | January 2006 (Revised May 2007)

    Endo Pharmaceuticals (F): Appeals Court Ruling

    Richard G. Hamermesh and Brian DeLacey

    Keywords: Lawsuits and Litigation; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (F): Appeals Court Ruling." Harvard Business School Supplement 806-082, January 2006. (Revised May 2007.)  View Details
    CiteView DetailsPurchase Related
  101. Supplement | HBS Case Collection | November 2006 (Revised May 2007)

    Corporate Venture Capital at Eli Lilly

    Richard G. Hamermesh

    Keywords: Management; Business Ventures; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G. "Corporate Venture Capital at Eli Lilly." Harvard Business School Video Supplement 807-705, November 2006. (Revised May 2007.)  View Details
    CiteView DetailsPurchase Related
  102. Case | HBS Case Collection | December 2005 (Revised May 2007)

    Cynthia Fisher and the Rearing of ViaCell

    Robert F. Higgins, Richard G. Hamermesh and Ingrid Vargas

    Describes the start up of Viacord, a Boston-based medical services firm founded by Cynthia Fisher (HBS MBA) in 1993. Told from Fisher's perspective, the entrepreneur details the conceptualization and launch of the business and the many obstacles and expenses faced in the company's first seven years. Fisher describes the venture capital negotiations and a merger with a biotech company that led to the creation of ViaCell in 2000. Fisher explains how her role changed from founder and CEO of Viacord to president and then board member of ViaCell, and carries the firm's story to the successful 2005 IPO.

    Keywords: Managerial Roles; Business Growth and Maturation; Entrepreneurship; Business Startups; Service Industry; Health Industry; Boston;

    Citation:

    Higgins, Robert F., Richard G. Hamermesh, and Ingrid Vargas. "Cynthia Fisher and the Rearing of ViaCell." Harvard Business School Case 806-002, December 2005. (Revised May 2007.)  View Details
    CiteView DetailsEducatorsPurchase Related
  103. Case | HBS Case Collection | December 2004 (Revised March 2007)

    Cutlass Capital, L.P.

    Richard G. Hamermesh and Brian DeLacey

    David Hetz and Jon Osgood are forming a new venture capital fund in 2001 to invest in health care start-ups. Describes their fundraising activities at a time when venture capital investing has reached an all-time high. Although their background skills and experiences fall outside venture capital, they have identified a large investor and a number of smaller investors to back their small fund. They believe their fund's strategy uniquely addresses the strategic needs of large, corporate acquirers. At the same time, their approach addresses venture capital's reliance on public markets for liquidity events--which all but evaporated with the dot-com collapse of March 2000. Hetz and Osgood face challenging negotiations to close the fund. Raises the question of whether there is a need for a fund like this at the time of the case. Supports discussion of specialized versus generalized venture capital funds.

    Keywords: Venture Capital; Negotiation Process; Entrepreneurship; Investment Funds; Health Care and Treatment; Business Startups; Health Industry; United States;

    Citation:

    Hamermesh, Richard G., and Brian DeLacey. "Cutlass Capital, L.P." Harvard Business School Case 805-075, December 2004. (Revised March 2007.)  View Details
    CiteView DetailsEducatorsPurchase Related
  104. Background Note | HBS Case Collection | January 2007 (Revised January 2007)

    Note on the U.S. Food and Drug Administration

    Robert F. Higgins, Richard G. Hamermesh and Virginia Fuller

    Describes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure.

    Keywords: Health; Governance Compliance; Policy; Product Development; Government and Politics; Pharmaceutical Industry; Medical Devices and Supplies Industry; Biotechnology Industry; Public Administration Industry; United States;

    Citation:

    Higgins, Robert F., Richard G. Hamermesh, and Virginia Fuller. "Note on the U.S. Food and Drug Administration." Harvard Business School Background Note 807-050, January 2007. (Revised January 2007.)  View Details
    CiteView DetailsEducatorsPurchase Related
  105. Background Note | HBS Case Collection | January 2007

    Note on Biotech Business Development

    Richard G. Hamermesh and Robert F. Higgins

    Describes the business development process in biotechnology companies. Topics covered include: participants in the licensing process and their interests, the major steps in the licensing process, the terms that are part of most agreements, and the most contentious issues that arise in the implementation of licensing agreements.

    Keywords: Agreements and Arrangements; Entrepreneurship; Intellectual Property; Biotechnology Industry;

    Citation:

    Hamermesh, Richard G., and Robert F. Higgins. "Note on Biotech Business Development." Harvard Business School Background Note 807-032, January 2007.  View Details
    CiteView DetailsEducatorsPurchase Related
  106. Supplement | HBS Case Collection | December 2006

    Dental Corp--video

    Richard G. Hamermesh

    Keywords: Media; Health Industry;

    Citation:

    Hamermesh, Richard G. "Dental Corp--video." Harvard Business School Video Supplement 807-703, December 2006.  View Details
    CiteView DetailsPurchase Related
  107. Teaching Note | HBS Case Collection | September 2006

    Corporate Venture Capital at Eli Lilly (TN)

    Richard G. Hamermesh and Erin Seefeld

    Keywords: Venture Capital; Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., and Erin Seefeld. "Corporate Venture Capital at Eli Lilly (TN)." Harvard Business School Teaching Note 807-059, September 2006.  View Details
    CiteView DetailsPurchase Related
  108. Case | HBS Case Collection | October 2005 (Revised September 2006)

    DentalCorp

    Richard G. Hamermesh and Ricardo Reisen de Pinho

    DentalCorp is the fifth largest provider of dental insurance in Brazil and has tripled its sales in the past two years. Whether to expand to Chile or to continue expansion in Brazil is the major strategic choice facing the company at the end of 2004.

    Keywords: International Finance; Expansion; Entrepreneurship; Health Care and Treatment; Global Strategy; Insurance Industry; Health Industry; Brazil; Chile;

    Citation:

    Hamermesh, Richard G., and Ricardo Reisen de Pinho. "DentalCorp." Harvard Business School Case 806-023, October 2005. (Revised September 2006.)  View Details
    CiteView DetailsEducatorsPurchase Related
  109. Supplement | HBS Case Collection | September 2006

    Wu Xi Pharmatech

    Richard G. Hamermesh

    Keywords: Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G. "Wu Xi Pharmatech." Harvard Business School Video Supplement 807-701, September 2006.  View Details
    CiteView DetailsPurchase Related
  110. Supplement | HBS Case Collection | June 2006

    Cutlass Capital, L.P.: Discussion with David Hetz and Jon Osgood

    Richard G. Hamermesh

    Keywords: Capital; Financial Services Industry;

    Citation:

    Hamermesh, Richard G. "Cutlass Capital, L.P.: Discussion with David Hetz and Jon Osgood." Harvard Business School Video Supplement 806-719, June 2006.  View Details
    CiteView DetailsPurchase Related
  111. Case | HBS Case Collection | September 2005 (Revised June 2006)

    WuXi PharmaTech

    Richard G. Hamermesh and Simin Zhou

    WuXi Pharmatech has gone from zero to $21 million in sales in three years. The company must decide its growth strategy and how best to finance and organize for rapid growth.

    Keywords: Growth Management; Capital Markets; Problems and Challenges; Pharmaceutical Industry; China;

    Citation:

    Hamermesh, Richard G., and Simin Zhou. "WuXi PharmaTech." Harvard Business School Case 806-003, September 2005. (Revised June 2006.)  View Details
    CiteView DetailsEducatorsPurchase Related
  112. Teaching Note | HBS Case Collection | May 2006

    WuXi PharmaTech (TN)

    Richard G. Hamermesh and Erin Seefeld

    Keywords: Pharmaceutical Industry;

    Citation:

    Hamermesh, Richard G., and Erin Seefeld. "WuXi PharmaTech (TN)." Harvard Business School Teaching Note 806-180, May 2006.  View Details
    CiteView DetailsPurchase Related
  113. Background Note | HBS Case Collection | April 2004 (Revised May 2006)

    Achieving Profitable Growth and Market Value

    James L. Heskett and Richard G. Hamermesh

    Provides an overview of how a new venture needs to change as it passes from the initial start-up to the growth phase. Explores how a venture's leadership, strategy, and execution need to evolve to deal with rapid growth.

    Keywords: Growth Management; Business Growth and Maturation; Business Startups; Change Management;

    Citation:

    Heskett, James L., and Richard G. Hamermesh. "Achieving Profitable Growth and Market Value." Harvard Business School Background Note 804-157, April 2004. (Revised May 2006.)  View Details
    CiteView DetailsEducatorsPurchase Related
  114. Teaching Note | HBS Case Collection | March 2006

    Cutlass Capital, L.P. (TN)

    Richard G. Hamermesh and Erin Seefeld

    Teaching Note to 805075.

    Keywords: Financial Services Industry;

    Citation:

    Hamermesh, Richard G., and Erin Seefeld. "Cutlass Capital, L.P. (TN)." Harvard Business School Teaching Note 806-155, March 2006.  View Details
    CiteView DetailsPurchase Related
  115. Teaching Note | HBS Case Collection | March 2006

    Stan Lapidus: Profile of a Medical Entrepreneur (TN)

    Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld

    Teaching Note to (805-087).

    Keywords: Personal Development and Career; Entrepreneurship; Business Startups; Biotechnology Industry; Pharmaceutical Industry;

    Citation:

    Higgins, Robert F., Richard G. Hamermesh, and Erin Seefeld. "Stan Lapidus: Profile of a Medical Entrepreneur (TN)." Harvard Business School Teaching Note 806-149, March 2006.  View Details
    CiteView DetailsPurchase Related
  116. Teaching Note | HBS Case Collection | March 2006

    Conor Medsystems (TN)

    Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld

    Teaching Note to (804-180).

    Keywords: Health Industry;

    Citation:

    Higgins, Robert F., Richard G. Hamermesh, and Erin Seefeld. "Conor Medsystems (TN)." Harvard Business School Teaching Note 806-150, March 2006.  View Details
    CiteView DetailsPurchase Related
  117. Teaching Note | HBS Case Collection | March 2006

    Fred Khosravi and AccessClosure (TN)

    Richard G. Hamermesh and Erin Seefeld

    Teaching Note to (806-044).

    Keywords: Entrepreneurship; Decision Choices and Conditions; Mergers and Acquisitions; Business Exit or Shutdown; Initial Public Offering; Medical Devices and Supplies Industry;

    Citation:

    Hamermesh, Richard G., and Erin Seefeld. "Fred Khosravi and AccessClosure (TN)." Harvard Business School Teaching Note 806-141, March 2006.  View Details
    CiteView DetailsPurchase Related
  118. Case | HBS Case Collection | January 2005 (Revised March 2006)

    Molecular Insight Pharmaceuticals, Inc.

    Richard G. Hamermesh and Edwin W. Parkinson III

    Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing. Should it continue its current strategy or change its approach? Includes color exhibits.

    Keywords: Intellectual Property; Health Care and Treatment; Pharmaceutical Industry; Health Industry;

    Citation:

    Hamermesh, Richard G., and Edwin W. Parkinson III. "Molecular Insight Pharmaceuticals, Inc." Harvard Business School Case 805-067, January 2005. (Revised March 2006.)  View Details
    CiteView DetailsEducatorsPurchase Related
  119. Teaching Note | HBS Case Collection | February 2006

    John Moran and the Orthopedics Industry (TN)

    Richard G. Hamermesh

    Teaching Note to 805026.

    Keywords: Health Industry;

    Citation:

    Hamermesh, Richard G. "John Moran and the Orthopedics Industry (TN)." Harvard Business School Teaching Note 806-125, February 2006.  View Details
    CiteView Details Related
  120. Case | HBS Case Collection | March 2003 (Revised January 2006)

    Threshold Sports

    Richard G. Hamermesh and Todd H Thedinga

    Describes the sales, marketing, and operating issues facing Threshold Sports, a small cycling event management company that produces the Pro Cycling Tour. Examines the issues facing the company as it approaches breakeven and attempts to grow the business substantially. The company must balance its growth objectives with a series of internal and external challenges. These include expanding the event to more cities, selling more sponsorships, expanding the TV coverage, and developing new revenue streams.

    Keywords: Growth Management; Bicycle Transportation; Service Delivery; Sports; Bicycle Industry; Service Industry;

    Citation:

    Hamermesh, Richard G., and Todd H Thedinga. "Threshold Sports." Harvard Business School Case 803-134, March 2003. (Revised January 2006.)  View Details
    CiteView DetailsEducatorsPurchase Related
  121. Supplement | HBS Case Collection | October 2005

    Shurgard Self-Storage (video)

    Richard G. Hamermesh

    Citation:

    Hamermesh, Richard G. "Shurgard Self-Storage (video)." Harvard Business School Video Supplement 806-711, October 2005.  View Details
    CiteView DetailsPurchase Related
  122. Supplement | HBS Case Collection | October 2005

    ProfitLogic: Scott Friend, CEO (DVD)

    Richard G. Hamermesh and Michael J. Roberts

    Citation:

    Hamermesh, Richard G., and Michael J. Roberts. "ProfitLogic: Scott Friend, CEO (DVD)." Harvard Business School Video Supplement 806-702, October 2005.  View Details
    CiteView DetailsPurchase Related
  123. Supplement | HBS Case Collection | October 2005

    Vialog Corporation (DVD)

    Richard G. Hamermesh

    Citation:

    Hamermesh, Richard G. "Vialog Corporation (DVD)." Harvard Business School Video Supplement 806-701, October 2005.  View Details
    CiteView DetailsPurchase Related
  124. Supplement | HBS Case Collection | October 2005

    MAC Development Corporation (DVD)

    Richard G. Hamermesh

    Citation:

    Hamermesh, Richard G. "MAC Development Corporation (DVD)." Harvard Business School Video Supplement 806-703, October 2005.  View Details
    CiteView DetailsPurchase Related
  125. Teaching Note | HBS Case Collection | September 2005

    ProfitLogic (TN)

    Richard G. Hamermesh and Michael J. Roberts

    Teaching Note to (9-802-110), (9-806-702), and (9-806-705).

    Keywords: Information Technology Industry; Service Industry;

    Citation:

    Hamermesh, Richard G., and Michael J. Roberts. "ProfitLogic (TN)." Harvard Business School Teaching Note 806-057, September 2005.  View Details
    CiteView DetailsPurchase Related
  126. Background Note | HBS Case Collection | January 2005 (Revised August 2005)

    A Note on Managing the Growing Venture

    Richard G. Hamermesh, James L. Heskett and Michael J. Roberts

    Focuses on the strategic and organizational challenges that confront growing enterprises and the entrepreneurs who lead them. Provides an overview of how a new venture needs to change as it passes from the initial start-up to the growth phase. Explores how a venture's leadership, strategy, and execution need to evolve to deal with rapid growth. A rewritten version of an earlier note.

    Keywords: Business Growth and Maturation; Leading Change;

    Citation:

    Hamermesh, Richard G., James L. Heskett, and Michael J. Roberts. "A Note on Managing the Growing Venture." Harvard Business School Background Note 805-092, January 2005. (Revised August 2005.)  View Details
    CiteView DetailsEducatorsPurchase Related
  127. Case | HBS Case Collection | March 2004 (Revised May 2005)

    Shurgard Self-Storage: Expansion to Europe

    Richard G. Hamermesh and Indra Reinbergs

    Shurgard, a U.S.-based firm that rents storage facilities to consumers and small businesses, is considering financing options for rapid expansion of its European operations. Five years after entering Europe, Shurgard Europe has opened 17 facilities in Belgium, France, and Sweden. Along the way, Shurgard has encountered skepticism from both European consumers and investors about the unfamiliar self-storage concept and internal debates on how much to adapt the U.S. business model to European lifestyles. Wall Street analysts also do not value the impact that the European expansion could have on Shurgard's U.S. performance as a publicly traded Real Estate Investment Trust (REIT). As an alternative, to finance this expansion, Shurgard received a proposed deal from a consortium of banks and other investors where they would provide private equity financing spaced over the next few years plus a line of credit. In return, the investors would receive a large share of Shurgard's equity and control of its board, which could force a public offering in less than two years. The decision focuses on whether Shurgard Europe should accept the conditions and valuation of the proposed deal or seek another deal at a later point in time. Students must assess whether the self-storage business model can deliver the growth rate in Europe that the company has promised his potential investors. Involves calculating some basic estimates of the company's value from financial exhibits (enterprise value using a pEBITDA multiple). Main focus is to assess this as an entrepreneurial venture. Students do not need to be familiar with REITs.

    Keywords: Private Equity; Valuation; Business Model; Governing and Advisory Boards; Entrepreneurship; Cross-Cultural and Cross-Border Issues; Service Industry; Belgium; France; Sweden; United States; Europe;

    Citation:

    Hamermesh, Richard G., and Indra Reinbergs. "Shurgard Self-Storage: Expansion to Europe." Harvard Business School Case 804-112, March 2004. (Revised May 2005.)  View Details
    CiteView DetailsEducatorsPurchase Related
  128. Case | HBS Case Collection | October 2004 (Revised February 2005)

    John Moran and the Orthopedics Industry

    Richard G. Hamermesh

    Reviews John Moran's 25-year career in the orthopedic industry and his current decision whether to start a hand and foot surgery company.

    Keywords: Business Startups; Decision Choices and Conditions; Personal Development and Career; Health Industry;

    Citation:

    Hamermesh, Richard G. "John Moran and the Orthopedics Industry." Harvard Business School Case 805-026, October 2004. (Revised February 2005.)  View Details
    CiteView DetailsFind at Harvard Related
  129. Case | HBS Case Collection | June 2001 (Revised November 2004)

    Kingsley Management

    Richard G. Hamermesh

    Includes a brief overview of key challenges facing recent HBS graduates seeking funding for a business, followed by a 22-page excerpt from the Kingsley Management business plan. Describes Matthew Lieb and Chris Jones, two of the partners who developed the business plan for Kingsley Management, as they prepare to meet with potential investors. Lieb and Jones are particularly concerned about the investors' financial returns and the structure of the new business entity (i.e., C-corp. vs. LLC). Outlines several questions facing Lieb and his co-founders, which students are asked to resolve.

    Keywords: Business Organization; Corporate Entrepreneurship; Business Plan; Opportunities; Investment Return; Organizational Structure;

    Citation:

    Hamermesh, Richard G. "Kingsley Management." Harvard Business School Case 801-474, June 2001. (Revised November 2004.)  View Details
    CiteView DetailsEducatorsPurchase Related
  130. Case | HBS Case Collection | December 2003 (Revised September 2004)

    Managing Segway's Early Development

    Richard G. Hamermesh and David Kiron

    Describes the early development of the Segway Human Transporter and focuses on the organizational issues that arise between the parent company and the new company that is being spun out to produce and market the Segway. Key issues are the distribution of bonuses and stock options.

    Keywords: Business Subsidiaries; Business Startups; Employee Stock Ownership Plan; Resource Allocation; Organizational Design; Technology Adoption;

    Citation:

    Hamermesh, Richard G., and David Kiron. "Managing Segway's Early Development." Harvard Business School Case 804-065, December 2003. (Revised September 2004.)  View Details
    CiteView DetailsEducatorsPurchase Related
  131. Teaching Note | HBS Case Collection | September 2004

    Managing Segway's Early Development (TN)

    Richard G. Hamermesh

    Teaching Note to (9-804-065).

    Citation:

    Hamermesh, Richard G. "Managing Segway's Early Development (TN)." Harvard Business School Teaching Note 805-016, September 2004.  View Details
    CiteView DetailsPurchase Related
  132. Teaching Note | HBS Case Collection | June 2004

    Pre-Money / Post-Money Tutorial (Instructor Guide)

    Richard G. Hamermesh and Michael J. Roberts

    Teaching Note to (9-803-703).

    Keywords: Entrepreneurship; Valuation; Finance; Online Technology;

    Citation:

    Hamermesh, Richard G., and Michael J. Roberts. "Pre-Money / Post-Money Tutorial (Instructor Guide)." Harvard Business School Teaching Note 804-195, June 2004.  View Details
    CiteView DetailsPurchase Related
  133. Case | HBS Case Collection | November 1998 (Revised July 2012)

    Explo Leisure Products

    Richard G. Hamermesh

    Tim Trowac and Dave Rahall, two former investment bankers, skillfully execute the leveraged buyout of a golf ball recycling company after working intensely on their due diligence, writing a business and financial plan, and developing the investment memorandum. Six months later, they question the competency of their management team, which they had assembled from former Explo employees rather than conduct extensive searches. Now financial results are poor. Trowac and Rahall need to explain the poor performance and come up with an action plan for their investors.

    Keywords: Selection and Staffing; Leveraged Buyouts; Business Plan; Performance; Management Teams; Business Strategy; Financial Strategy; Business and Shareholder Relations; Green Technology Industry; Sports Industry;

    Citation:

    Hamermesh, Richard G. "Explo Leisure Products." Harvard Business School Case 399-053, November 1998. (Revised July 2012.)  View Details
    CiteView DetailsEducatorsPurchase Related
  134. Teaching Note | HBS Case Collection | January 2004

    Resourcery, Ltd. (TN)

    Richard G. Hamermesh

    Teaching Note to (9-803-148).

    Keywords: Nigeria;

    Citation:

    Hamermesh, Richard G. "Resourcery, Ltd. (TN)." Harvard Business School Teaching Note 804-008, January 2004.  View Details
    CiteView DetailsPurchase Related
  135. Case | HBS Case Collection | March 2003 (Revised November 2003)

    Resourcery, Ltd.

    Richard G. Hamermesh and Feyi A. Boroffice

    Recounts the story of how a successful Nigerian entrepreneur has expanded his systems integration/networking business. He now faces the problem of raising growth capital in a developing country.

    Keywords: Venture Capital; Growth Management; Expansion; Race; Entrepreneurship; Developing Countries and Economies;

    Citation:

    Hamermesh, Richard G., and Feyi A. Boroffice. "Resourcery, Ltd." Harvard Business School Case 803-148, March 2003. (Revised November 2003.)  View Details
    CiteView DetailsEducators Related
  136. Teaching Note | HBS Case Collection | March 2003 (Revised June 2003)

    Threshold Sports (TN)

    Richard G. Hamermesh and Todd H Thedinga

    Teaching Note for (9-803-134).

    Keywords: Sports Industry;

    Citation:

    Hamermesh, Richard G., and Todd H Thedinga. "Threshold Sports (TN)." Harvard Business School Teaching Note 803-135, March 2003. (Revised June 2003.)  View Details
    CiteView DetailsPurchase Related
  137. Case | HBS Case Collection | March 2002 (Revised June 2003)

    MAC Development Corporation

    Richard G. Hamermesh and Colleen McCaffrey

    Deals with MAC Development's efforts to develop a 41-acre site near Chicago. Reviews two years of efforts and highlights the remaining issues of: 1) gaining town approval for development and tax reductions, 2) meeting the bank's debt covenants, including finding a buyer for the first lot, and 3) agreeing on a final purchase price with the seller. Includes color exhibits.

    Keywords: Risk Management; Taxation; Financial Instruments; Borrowing and Debt; Asset Pricing; Construction Industry; Chicago;

    Citation:

    Hamermesh, Richard G., and Colleen McCaffrey. "MAC Development Corporation." Harvard Business School Case 802-140, March 2002. (Revised June 2003.)  View Details
    CiteView DetailsEducatorsPurchase Related
  138. Case | HBS Case Collection | January 2002 (Revised May 2003)

    ProfitLogic

    Richard G. Hamermesh, Michael J. Roberts and Taslim Pirmohamed

    Describes an "application software" company that has been through several evolutions--from consulting firm to applications service provider (ASP). The firm has received significant venture funding to pursue the ASP model but this has not worked, at least at the time the case ends. The company faces a choice: continuing with its current ASP business model, increasing its burn rate to convert to a licensed software model, or decreasing its burn rate to offer a more custom version of the ASP product.

    Keywords: History; Business Model; Venture Capital; Cash Flow; Decision Choices and Conditions; Balanced Scorecard; Information Technology Industry; Service Industry;

    Citation:

    Hamermesh, Richard G., Michael J. Roberts, and Taslim Pirmohamed. "ProfitLogic." Harvard Business School Case 802-110, January 2002. (Revised May 2003.)  View Details
    CiteView DetailsEducatorsPurchase Related
  139. Supplement | HBS Case Collection | May 2003

    Jim Sharpe: Extrusion Technology, Inc.

    Richard G. Hamermesh and Paul W. Marshall

    Jim Sharpe discusses his early career at General Electric to his decision to purchase and run a small company. The discussion includes a detailed acquisition financing proposal, which resulted in Sharpe being able to raise virtually all of the financing from some combination of the seller and the bank.

    Keywords: Personal Development and Career; Entrepreneurship; Business Startups; Mergers and Acquisitions; Financing and Loans;

    Citation:

    Hamermesh, Richard G., and Paul W. Marshall. "Jim Sharpe: Extrusion Technology, Inc." Harvard Business School Video Supplement 803-803, May 2003.  View Details
    CiteView DetailsPurchase Related
  140. Teaching Note | HBS Case Collection | June 2001 (Revised April 2003)

    Kingsley Management TN

    Richard G. Hamermesh and Michelle Lutz

    Teaching Note for (801-474).

    Citation:

    Hamermesh, Richard G., and Michelle Lutz. "Kingsley Management TN." Harvard Business School Teaching Note 801-484, June 2001. (Revised April 2003.)  View Details
    CiteView DetailsPurchase Related
  141. Tutorial | February 2003

    Pre-Money / Post-Money Tutorial

    Richard G. Hamermesh, Nitin Nohria, Michael J. Roberts, Arleen Ahearn-Cavanaugh and Sal Darji

    An online, interactive tutorial that addresses issues surrounding entrepreneurial valuations. Topics include: the difference between an implied and a "bottom-up" valuation; the difference between pre-money and post-money valuations; the calculation of pre-money and post-money valuations; and the creation and interpretation of a capitalization table.

    Keywords: Money;

    Citation:

    "Pre-Money / Post-Money Tutorial." Harvard Business School Tutorial 803-703, February 2003.  View Details
    CiteView DetailsPurchase Related
  142. Teaching Note | HBS Case Collection | July 2002

    MAC Development Corporation (TN)

    Richard G. Hamermesh

    Teaching Note for (2-802-140), (9-806-703), and (9-806-706).

    Keywords: Construction Industry; Chicago;

    Citation:

    Hamermesh, Richard G. "MAC Development Corporation (TN)." Harvard Business School Teaching Note 803-024, July 2002.  View Details
    CiteView DetailsPurchase Related
  143. Case | HBS Case Collection | January 2002 (Revised July 2002)

    Vialog Corporation

    Richard G. Hamermesh and Michele Lutz

    Traces the origin of Vialog Corp.--from its founding in 1996 through a roll-up of several independent teleconferencing companies in 1997 and its initial public offering (1999) and eventually to a potential merger or acquisition in June 2000. The company has grown rapidly and has the option of merging with an Internet company or another strategic partner, or selling to a European strategic partner.

    Keywords: History; Business Exit or Shutdown; Internet; Corporate Entrepreneurship; Partners and Partnerships; Initial Public Offering; Business Growth and Maturation; Mergers and Acquisitions; Business Processes; Information Technology Industry; Europe;

    Citation:

    Hamermesh, Richard G., and Michele Lutz. "Vialog Corporation." Harvard Business School Case 802-008, January 2002. (Revised July 2002.)  View Details
    CiteView DetailsEducatorsPurchase Related
  144. Teaching Note | HBS Case Collection | January 2002 (Revised July 2002)

    Vialog Corporation (TN)

    Richard G. Hamermesh and Michele Lutz

    Citation:

    Hamermesh, Richard G., and Michele Lutz. "Vialog Corporation (TN)." Harvard Business School Teaching Note 802-053, January 2002. (Revised July 2002.)  View Details
    CiteView DetailsPurchase Related
  145. Background Note | HBS Case Collection | January 2002

    Note on Business Model Analysis for the Entrepreneur

    Richard G. Hamermesh, Paul W. Marshall and Taslim Pirmohamed

    Describes the primary elements and defining characteristics of a company's business model from the perspective of an entrepreneur. Introduces several analytic techniques and provides illustrative examples of business models to support the analytic framework presented.

    Keywords: Business Model; Entrepreneurship; Framework; Mathematical Methods; Opportunities; Perspective;

    Citation:

    Hamermesh, Richard G., Paul W. Marshall, and Taslim Pirmohamed. "Note on Business Model Analysis for the Entrepreneur." Harvard Business School Background Note 802-048, January 2002.  View Details
    CiteView DetailsEducatorsPurchase Related
  146. Teaching Note | HBS Case Collection | January 2001 (Revised May 2001)

    Return Logic, Inc. (A) and (B) TN

    Richard G. Hamermesh and Michele Lutz

    Teaching Note for (9-801-167) and (9-801-168).

    Citation:

    Hamermesh, Richard G., and Michele Lutz. "Return Logic, Inc. (A) and (B) TN." Harvard Business School Teaching Note 801-366, January 2001. (Revised May 2001.)  View Details
    CiteView DetailsPurchase Related
  147. Case | HBS Case Collection | February 2001 (Revised May 2001)

    Balance, Inc. (A)

    Richard G. Hamermesh and Michele Lutz

    Focuses on an entrepreneur who founded a successful health-food store and seeks to expand his retail concept. Illustrates the challenges he faces as he recruits his top management team.

    Keywords: Distribution Channels; Executive Compensation; Agreements and Arrangements; Outcome or Result; Recruitment; Management Teams; Selection and Staffing; Food and Beverage Industry;

    Citation:

    Hamermesh, Richard G., and Michele Lutz. "Balance, Inc. (A)." Harvard Business School Case 801-169, February 2001. (Revised May 2001.)  View Details
    CiteView DetailsFind at Harvard Related
  148. Teaching Note | HBS Case Collection | February 2001 (Revised May 2001)

    Balance, Inc. (A) and (B) TN

    Richard G. Hamermesh and Michele Lutz

    Teaching Note for (9-801-169) and (9-801-170).

    Keywords: Entrepreneurship; Food and Beverage Industry;

    Citation:

    Hamermesh, Richard G., and Michele Lutz. "Balance, Inc. (A) and (B) TN." Harvard Business School Teaching Note 801-372, February 2001. (Revised May 2001.)  View Details
    CiteView Details Related
  149. Case | HBS Case Collection | January 2001 (Revised May 2001)

    Return Logic, Inc. (A)

    Richard G. Hamermesh and Michele Lutz

    Follows three graduating HBS students as they build a business-to-business Internet venture and highlights the challenges they confront in structuring financing terms with venture capitalists. Requires students to carefully read a six-page term sheet to identify which provisions should and should not be accepted.

    Keywords: Venture Capital; Investment Funds; Private Equity; Internet; Negotiation Deal; Entrepreneurship;

    Citation:

    Hamermesh, Richard G., and Michele Lutz. "Return Logic, Inc. (A)." Harvard Business School Case 801-167, January 2001. (Revised May 2001.)  View Details
    CiteView DetailsEducatorsPurchase Related
  150. Case | HBS Case Collection | January 2001 (Revised May 2001)

    Return Logic, Inc. (B)

    Richard G. Hamermesh and Michele Lutz

    Highlights how multiple rounds of financing work in practice and illustrates how terms agreed to in early-stage financing deals have an impact in later financing rounds. Also illustrates ethical issues that entrepreneurs confront as they build "dot-com" ventures.

    Keywords: Venture Capital; Investment Funds; Private Equity; Internet; Negotiation Deal; Entrepreneurship; Ethics;

    Citation:

    Hamermesh, Richard G., and Michele Lutz. "Return Logic, Inc. (B)." Harvard Business School Case 801-168, January 2001. (Revised May 2001.)  View Details
    CiteView DetailsEducatorsPurchase Related
  151. Case | HBS Case Collection | January 2001 (Revised April 2001)

    Lawyers & Leases

    Richard G. Hamermesh and Michele Lutz

    Profiles Rajath Chaundry, an aspiring entrepreneur, as he attempts to secure office space for his growing team, select a lawyer, and continue to build his fledgling enterprise, eLearning.com. Designed to be used in an entrepreneurial management or small business course to illustrate the importance of early negotiations in the life of a business venture.

    Keywords: Entrepreneurship; Business or Company Management; Business Ventures; Corporate Entrepreneurship; Intellectual Property; Management Succession; Leasing; Negotiation; Education Industry; Legal Services Industry;

    Citation:

    Hamermesh, Richard G., and Michele Lutz. "Lawyers & Leases." Harvard Business School Case 801-166, January 2001. (Revised April 2001.)  View Details
    CiteView DetailsEducatorsPurchase Related
  152. Case | HBS Case Collection | February 2001 (Revised April 2001)

    Balance, Inc. (B)

    Richard G. Hamermesh and Michele Lutz

    Supplements the (A) case.

    Keywords: Entrepreneurship; Food and Beverage Industry;

    Citation:

    Hamermesh, Richard G., and Michele Lutz. "Balance, Inc. (B)." Harvard Business School Case 801-170, February 2001. (Revised April 2001.)  View Details
    CiteView DetailsFind at Harvard Related
  153. Teaching Note | HBS Case Collection | January 2001 (Revised April 2001)

    Lawyers & Leases TN

    Richard G. Hamermesh and Michele Lutz

    Teaching Note for (9-801-166).

    Keywords: Contracts; Negotiation; Entrepreneurship; Internet; Education; Education Industry;

    Citation:

    Hamermesh, Richard G., and Michele Lutz. "Lawyers & Leases TN." Harvard Business School Teaching Note 801-353, January 2001. (Revised April 2001.)  View Details
    CiteView DetailsPurchase Related
  154. Supplement | HBS Case Collection | November 1999

    STT Aerospace: Interview with Charles Damon, Chairman and CEO, February 8, 1999

    Richard G. Hamermesh and Jeremy Dann

    Citation:

    Hamermesh, Richard G., and Jeremy Dann. "STT Aerospace: Interview with Charles Damon, Chairman and CEO, February 8, 1999." Harvard Business School Video Supplement 300-502, November 1999.  View Details
    CiteView DetailsPurchase Related
  155. Supplement | HBS Case Collection | January 1999 (Revised October 1999)

    STT Aerospace, Supplement

    Richard G. Hamermesh and Jeremy Dann

    Supplements the case.

    Keywords: Aerospace Industry;

    Citation:

    Hamermesh, Richard G., and Jeremy Dann. "STT Aerospace, Supplement." Harvard Business School Supplement 399-078, January 1999. (Revised October 1999.)  View Details
    CiteView DetailsFind at Harvard Related
  156. Case | HBS Case Collection | February 1999 (Revised June 1999)

    Bloomberg L.P.

    Clayton M. Christensen, Richard G. Hamermesh and Jeremy Dann

    Michael Bloomberg founded his company to provide customers quick access to financial market data and analytical tools for understanding that data. As Bloomberg L.P. grew quickly,entered the ranks of "large, established companies," it grappled with a whole new range of human resources, organizational, and corporate culture issues.

    Keywords: Human Resources; Management Analysis, Tools, and Techniques; Organizational Culture; Organizational Structure; Problems and Challenges;

    Citation:

    Christensen, Clayton M., Richard G. Hamermesh, and Jeremy Dann. "Bloomberg L.P." Harvard Business School Case 399-081, February 1999. (Revised June 1999.)  View Details
    CiteView DetailsFind at Harvard Related
  157. Teaching Note | HBS Case Collection | June 1999

    STT Aerospace and Supplement TN

    Richard G. Hamermesh

    Teaching Note for (9-399-056) and (9-399-078).

    Keywords: Aerospace Industry;

    Citation:

    Hamermesh, Richard G. "STT Aerospace and Supplement TN." Harvard Business School Teaching Note 399-169, June 1999.  View Details
    CiteView Details Related
  158. Case | HBS Case Collection | December 1998 (Revised June 1999)

    STT Aerospace

    Richard G. Hamermesh and Jeremy Dann

    Experienced entrepreneur Charles Damon conducted a "roll-up" from 1987-1994 within the commercial airliner interior products industry. Damon's company, STT Aerospace, took advantage of an industry-wide recession in the early 1990s by buying when asset prices were low. The strategy's success was borne out by the company's growth and success in the marketplace. However, the company faced its own set of problems as the industry downturn continued. Critical decisions to be made at the end of the case include: 1) Whether or not STT should continue its acquisition strategy in the face of declining profits; 2) If the company should reset the strike price of options packages, a big part of employee compensation; and 3) If they should invest in a breakthrough high-tech product.

    Keywords: Retention; Business Strategy; Selection and Staffing; Entrepreneurship; Financial Crisis; Growth and Development Strategy; Compensation and Benefits; Employee Stock Ownership Plan; Acquisition; Product Development; Aerospace Industry;

    Citation:

    Hamermesh, Richard G., and Jeremy Dann. "STT Aerospace." Harvard Business School Case 399-056, December 1998. (Revised June 1999.)  View Details
    CiteView DetailsFind at Harvard Related
  159. Supplement | HBS Case Collection | September 1983 (Revised May 1999)

    Orthoteks USA (B3)

    Joseph L. Badaracco Jr. and Richard G. Hamermesh

    Supplements the (A) case.

    Keywords: Health Industry; United States;

    Citation:

    Badaracco, Joseph L., Jr., and Richard G. Hamermesh. "Orthoteks USA (B3)." Harvard Business School Supplement 384-060, September 1983. (Revised May 1999.)  View Details
    CiteView DetailsPurchase Related
  160. Teaching Note | HBS Case Collection | May 1999

    Explo Leisure Products TN

    Richard G. Hamermesh

    Teaching Note for (9-399-053).

    Keywords: Search Funds;

    Citation:

    Hamermesh, Richard G. "Explo Leisure Products TN." Harvard Business School Teaching Note 399-168, May 1999.  View Details
    CiteView DetailsPurchase Related
  161. Case | HBS Case Collection | December 1998 (Revised May 1999)

    Specialty Medical Chemicals

    Richard G. Hamermesh and Lucinda Doran

    A new general manager is supposed to rekindle growth. Seven months later, he questions the abilities of his direct reports. An organizational psychologist is brought in to assess his people. The general manager now has to decide who to keep and how to structure his direct report team.

    Keywords: Decisions; Employees; Leadership Development; Management Teams; Organizational Structure; Cognition and Thinking;

    Citation:

    Hamermesh, Richard G., and Lucinda Doran. "Specialty Medical Chemicals." Harvard Business School Case 399-094, December 1998. (Revised May 1999.)  View Details
    CiteView DetailsEducatorsPurchase Related
  162. Teaching Note | HBS Case Collection | June 1998

    Mitek Corporation TN

    Richard G. Hamermesh

    Citation:

    Hamermesh, Richard G. "Mitek Corporation TN." Harvard Business School Teaching Note 398-181, June 1998.  View Details
    CiteView Details Related
  163. Teaching Note | HBS Case Collection | June 1998

    PC&D, Inc. TN

    Richard G. Hamermesh

    Teaching Note for (9-380-072).

    Citation:

    Hamermesh, Richard G. "PC&D, Inc. TN." Harvard Business School Teaching Note 398-183, June 1998.  View Details
    CiteView DetailsPurchase Related
  164. Teaching Note | HBS Case Collection | June 1998

    Orthoteks USA Series TN

    Joseph L. Badaracco Jr. and Richard G. Hamermesh

    Teaching Note for (9-384-057), (9-384-058), (9-384-059), (9-384-060), (9-384-061), and (9-384-062).

    Keywords: Health Industry; United States; Switzerland;

    Citation:

    Badaracco, Joseph L., Jr., and Richard G. Hamermesh. "Orthoteks USA Series TN." Harvard Business School Teaching Note 398-126, June 1998.  View Details
    CiteView DetailsPurchase Related
  165. Teaching Note | HBS Case Collection | June 1995

    Cleveland Twist Drill (A) and (B) TN

    Richard G. Hamermesh and Joseph L. Bower

    Teaching Note for (9-384-083) and (9-384-163).

    Citation:

    Hamermesh, Richard G., and Joseph L. Bower. "Cleveland Twist Drill (A) and (B) TN." Harvard Business School Teaching Note 395-236, June 1995.  View Details
    CiteView DetailsPurchase Related
  166. Case | HBS Case Collection | April 1981 (Revised March 1993)

    General Electric: Strategic Position--1981

    Francis Aguilar and Richard G. Hamermesh

    Describes the introduction and evolution of General Electric's strategic planning system from the 1960s to Jack Welch's tenure. Allows discussion of the interplay of problems and circumstances to the evolution of the strategic planning system, and how Welch might use or alter the system to meet the challenge of growth.

    Keywords: Strategic Planning; Growth Management;

    Citation:

    Aguilar, Francis, and Richard G. Hamermesh. "General Electric: Strategic Position--1981." Harvard Business School Case 381-174, April 1981. (Revised March 1993.)  View Details
    CiteView DetailsEducatorsPurchase Related
  167. Case | HBS Case Collection | May 1985 (Revised March 1993)

    General Electric Co.--1984

    Francis Aguilar and Richard G. Hamermesh

    Describes the first four years of Jack Welch's tenure as CEO of the General Electric Co. Deals with the ways Welch has tried to change GE's strategy and planning activities and his attempts to make the company more entrepreneurial.

    Keywords: Management Teams; Management Style; Change Management; Strategic Planning; Corporate Strategy; Corporate Entrepreneurship; Organizational Change and Adaptation;

    Citation:

    Aguilar, Francis, and Richard G. Hamermesh. "General Electric Co.--1984." Harvard Business School Case 385-315, May 1985. (Revised March 1993.)  View Details
    CiteView DetailsEducatorsPurchase Related
  168. Case | HBS Case Collection | September 1983 (Revised July 1991)

    Orthoteks USA (A)

    Joseph L. Badaracco Jr. and Richard G. Hamermesh

    A series on implementing strategy as the head of the U.S. subsidiary of a successful Swiss medical products firm. Traces the actions of the CEO over a four year period and highlights his negotiations with the Swiss parent and the way functional components of the strategy were developed and integrated. Describes Hans Wyss' first eight months as CEO of Orthoteks USA.

    Keywords: Business Subsidiaries; Trade; Health Care and Treatment; Leadership Style; Agreements and Arrangements; Strategy; Health Industry; Switzerland; United States;

    Citation:

    Badaracco, Joseph L., Jr., and Richard G. Hamermesh. "Orthoteks USA (A)." Harvard Business School Case 384-057, September 1983. (Revised July 1991.)  View Details
    CiteView DetailsEducatorsPurchase Related
  169. Case | HBS Case Collection | May 1984 (Revised May 1989)

    Cleveland Twist Drill (B)

    Richard G. Hamermesh

    Describes events at Cleveland Twist Drill between April 1982 and February 1983. Jim Bartlett's approach to the union and the implementation of the "move strategy" are described. Students are asked to evaluate these actions and to develop plans for dealing with current problems and with recent overtures from the union president.

    Keywords: History; Management Style; Leadership Style; Standards; Power and Influence;

    Citation:

    Hamermesh, Richard G. "Cleveland Twist Drill (B)." Harvard Business School Case 384-163, May 1984. (Revised May 1989.)  View Details
    CiteView DetailsEducatorsPurchase Related
  170. Case | HBS Case Collection | September 1983 (Revised December 1988)

    Cleveland Twist Drill (A)

    Richard G. Hamermesh

    Deals with the problems of implementing strategy in a declining industry and the negotiation of strategy with external constituencies, particularly labor unions. Traces Jim Bartlett's first nine months as president and asks for a plan of action.

    Keywords: Decision Choices and Conditions; Management Style; Negotiation Tactics; Labor and Management Relations; Corporate Strategy;

    Citation:

    Hamermesh, Richard G. "Cleveland Twist Drill (A)." Harvard Business School Case 384-083, September 1983. (Revised December 1988.)  View Details
    CiteView DetailsEducatorsPurchase Related
  171. Background Note | HBS Case Collection | September 1982 (Revised October 1988)

    Note on Implementing Strategy

    Richard G. Hamermesh

    Presents a framework for thinking about problems of implementing strategy. Defines the tasks of implementation and the range of implementation situations, then develops four approaches to implementation and reviews a range of implementation skills. Intended for use in Business Policy II in conjunction with case studies.

    Keywords: Strategy;

    Citation:

    Hamermesh, Richard G. "Note on Implementing Strategy." Harvard Business School Background Note 383-015, September 1982. (Revised October 1988.)  View Details
    CiteView DetailsEducatorsPurchase Related
  172. Case | HBS Case Collection | February 1988

    Crown Cork & Seal Co., Inc. (Condensed)

    Richard G. Hamermesh and Richard S. Rosenbloom

    A condensed version of Crown Cork & Seal Co., Inc. The principal changes are the elimination of details about the early history of the company and condensation of the final section, Outlook for the Future.

    Keywords: Risk and Uncertainty; Industry Growth; Environmental Sustainability; Business Strategy; Trends; Manufacturing Industry;

    Citation:

    Hamermesh, Richard G., and Richard S. Rosenbloom. "Crown Cork & Seal Co., Inc. (Condensed)." Harvard Business School Case 388-096, February 1988.  View Details
    CiteView DetailsEducatorsPurchase Related
  173. Case | HBS Case Collection | August 1977 (Revised April 1987)

    Crown Cork & Seal Co., Inc.

    Richard G. Hamermesh

    Describes the technical, economic, and competitive trends in the metal container industry. The strategy of Crown Cork and Seal is then described in relation to these trends. Focuses on two immediate threats to Crown's strategy: the future of aerosol cans, given the ozone problem; and the impact of the banning of nonreturnable containers.

    Keywords: Risk and Uncertainty; Business History; Industry Growth; Environmental Sustainability; Business Strategy; Trends; Manufacturing Industry;

    Citation:

    Hamermesh, Richard G. "Crown Cork & Seal Co., Inc." Harvard Business School Case 378-024, August 1977. (Revised April 1987.)  View Details
    CiteView DetailsEducatorsPurchase Related
  174. Supplement | HBS Case Collection | September 1983 (Revised July 1986)

    Orthoteks USA (C)

    Joseph L. Badaracco Jr. and Richard G. Hamermesh

    Supplements the (A) case.

    Keywords: Health Care and Treatment; Health Industry; United States;

    Citation:

    Badaracco, Joseph L., Jr., and Richard G. Hamermesh. "Orthoteks USA (C)." Harvard Business School Supplement 384-061, September 1983. (Revised July 1986.)  View Details
    CiteView DetailsPurchase Related
  175. Case | HBS Case Collection | October 1980 (Revised June 1986)

    International Harvester (B1)

    Richard G. Hamermesh and Evelyn T. Christiansen

    Keywords: Manufacturing Industry; Agriculture and Agribusiness Industry;

    Citation:

    Hamermesh, Richard G., and Evelyn T. Christiansen. "International Harvester (B1)." Harvard Business School Case 381-053, October 1980. (Revised June 1986.)  View Details
    CiteView DetailsFind at Harvard Related
  176. Teaching Note | HBS Case Collection | June 1986

    International Harvester (A), (B1), (B2), (B3), (B4), (C), and (D), Teaching Note

    Richard G. Hamermesh and Evelyn T. Christiansen

    Citation:

    Hamermesh, Richard G., and Evelyn T. Christiansen. "International Harvester (A), (B1), (B2), (B3), (B4), (C), and (D), Teaching Note." Harvard Business School Teaching Note 386-125, June 1986.  View Details
    CiteView Details Related
  177. Supplement | HBS Case Collection | April 1986

    Lyric Dinner Theatre: Deborah Denenberg, General Manager, Video

    Richard G. Hamermesh

    Presents Deborah Denenberg, general manager, answering questions about her successful turnaround of an ailing dinner theatre.

    Keywords: Managerial Roles; Restructuring; Business Ventures; Arts; Entertainment and Recreation Industry; Food and Beverage Industry;

    Citation:

    Hamermesh, Richard G. "Lyric Dinner Theatre: Deborah Denenberg, General Manager, Video." Harvard Business School Video Supplement 886-523, April 1986.  View Details
    CiteView DetailsPurchase Related
  178. Case | HBS Case Collection | October 1979 (Revised March 1986)

    PC&D, Inc.

    Evelyn T. Christiansen and Richard G. Hamermesh

    Covers history of PC&D from 1960 to 1975 as it grows from a single business firm to a diversified firm. Emphasizes the use of subsidiaries for product development and fast growth. Other issues include problems of a new CEO in keeping control of fast growing divisions.

    Keywords: Leadership; Business Subsidiaries; Diversification; Growth Management; Product Development;

    Citation:

    Christiansen, Evelyn T., and Richard G. Hamermesh. "PC&D, Inc." Harvard Business School Case 380-072, October 1979. (Revised March 1986.)  View Details
    CiteView DetailsEducatorsPurchase Related
  179. Supplement | HBS Case Collection | January 1986

    General Electric--1984: John F. Welch, Jr., Video

    Richard G. Hamermesh and Francis Aguilar

    Citation:

    Hamermesh, Richard G., and Francis Aguilar. "General Electric--1984: John F. Welch, Jr., Video." Harvard Business School Video Supplement 886-529, January 1986.  View Details
    CiteView DetailsPurchase Related
  180. Teaching Note | HBS Case Collection | April 1979 (Revised December 1985)

    Dexter Corp., Teaching Note

    Richard G. Hamermesh

    Citation:

    Hamermesh, Richard G. "Dexter Corp., Teaching Note." Harvard Business School Teaching Note 379-172, April 1979. (Revised December 1985.)  View Details
    CiteView Details Related
  181. Teaching Note | HBS Case Collection | February 1975 (Revised October 1985)

    Fuqua Industries (A), (B), and (C), Teaching Note

    Malcolm S. Salter and Richard G. Hamermesh

    Citation:

    Salter, Malcolm S., and Richard G. Hamermesh. "Fuqua Industries (A), (B), and (C), Teaching Note." Harvard Business School Teaching Note 375-280, February 1975. (Revised October 1985.)  View Details
    CiteView Details Related
  182. Teaching Note | HBS Case Collection | October 1977 (Revised October 1985)

    Crown Cork & Seal Co., Inc., Teaching Note

    Richard G. Hamermesh

    Teaching Note for (9-378-024).

    Keywords: Manufacturing Industry;

    Citation:

    Hamermesh, Richard G. "Crown Cork & Seal Co., Inc., Teaching Note." Harvard Business School Teaching Note 378-108, October 1977. (Revised October 1985.)  View Details
    CiteView DetailsPurchase Related
  183. Teaching Note | HBS Case Collection | March 1975 (Revised October 1985)

    Federated Department Stores, Teaching Note

    Joseph L. Bower and Richard G. Hamermesh

    Keywords: Retail Industry;

    Citation:

    Bower, Joseph L., and Richard G. Hamermesh. "Federated Department Stores, Teaching Note." Harvard Business School Teaching Note 375-304, March 1975. (Revised October 1985.)  View Details
    CiteView Details Related
  184. Supplement | HBS Case Collection | September 1983 (Revised September 1985)

    Orthoteks USA (B1)

    Joseph L. Badaracco Jr. and Richard G. Hamermesh

    Supplements the (A) case.

    Keywords: Health Industry; United States;

    Citation:

    Badaracco, Joseph L., Jr., and Richard G. Hamermesh. "Orthoteks USA (B1)." Harvard Business School Supplement 384-058, September 1983. (Revised September 1985.)  View Details
    CiteView DetailsPurchase Related
  185. Supplement | HBS Case Collection | September 1983 (Revised September 1985)

    Orthoteks USA (B2)

    Joseph L. Badaracco Jr. and Richard G. Hamermesh

    Supplements the (A) case.

    Keywords: Health Industry; United States;

    Citation:

    Badaracco, Joseph L., Jr., and Richard G. Hamermesh. "Orthoteks USA (B2)." Harvard Business School Supplement 384-059, September 1983. (Revised September 1985.)  View Details
    CiteView DetailsPurchase Related
  186. Case | HBS Case Collection | November 1974 (Revised June 1985)

    Federated Department Stores

    Joseph L. Bower and Richard G. Hamermesh

    Keywords: Retail Industry;

    Citation:

    Bower, Joseph L., and Richard G. Hamermesh. "Federated Department Stores." Harvard Business School Case 375-147, November 1974. (Revised June 1985.)  View Details
    CiteView DetailsFind at Harvard Related
  187. Case | HBS Case Collection | November 1981 (Revised May 1985)

    General Electric: Business Development

    Francis Aguilar and Richard G. Hamermesh

    Keywords: Business Growth and Maturation; Diversification;

    Citation:

    Aguilar, Francis, and Richard G. Hamermesh. "General Electric: Business Development." Harvard Business School Case 382-092, November 1981. (Revised May 1985.)  View Details
    CiteView DetailsFind at Harvard Related
  188. Supplement | HBS Case Collection | April 1985

    Cleveland Twist Drill: Jim Bartlett, Video

    Richard G. Hamermesh and Daniel F. Muzyka

    Presents a question and answer session with Jim Bartlett, president of Cleveland Twist Drill. Edited into three parts. Bartlett provides additional insights into the case situation and also describes subsequent events at the company.

    Keywords: Management Teams; Corporate Strategy; Policy; Construction Industry; Consumer Products Industry;

    Citation:

    Hamermesh, Richard G., and Daniel F. Muzyka. "Cleveland Twist Drill: Jim Bartlett, Video." Harvard Business School Video Supplement 885-513, April 1985.  View Details
    CiteView DetailsPurchase Related
  189. Case | HBS Case Collection | October 1980 (Revised January 1985)

    International Harvester (A)

    Richard G. Hamermesh and Evelyn T. Christiansen

    Keywords: Agriculture and Agribusiness Industry; Manufacturing Industry;

    Citation:

    Hamermesh, Richard G., and Evelyn T. Christiansen. "International Harvester (A)." Harvard Business School Case 381-052, October 1980. (Revised January 1985.)  View Details
    CiteView DetailsFind at Harvard Related
  190. Case | HBS Case Collection | November 1982 (Revised January 1985)

    International Harvester (D)

    Richard G. Hamermesh

    Keywords: Agriculture and Agribusiness Industry; Manufacturing Industry;

    Citation:

    Hamermesh, Richard G. "International Harvester (D)." Harvard Business School Case 383-035, November 1982. (Revised January 1985.)  View Details
    CiteView DetailsFind at Harvard Related
  191. Case | HBS Case Collection | February 1979 (Revised September 1983)

    Dexter Corp.

    Richard G. Hamermesh

    Citation:

    Hamermesh, Richard G. "Dexter Corp." Harvard Business School Case 379-112, February 1979. (Revised September 1983.)  View Details
    CiteView DetailsFind at Harvard Related
  192. Supplement | HBS Case Collection | September 1983

    Orthoteks USA (D)

    Joseph L. Badaracco Jr. and Richard G. Hamermesh

    Supplements the (A) case.

    Keywords: Health Industry; United States; Switzerland;

    Citation:

    Badaracco, Joseph L., Jr., and Richard G. Hamermesh. "Orthoteks USA (D)." Harvard Business School Supplement 384-062, September 1983.  View Details
    CiteView DetailsPurchase Related
  193. Supplement | HBS Case Collection | June 1983

    General Electric: John F. Welch, Jr., Chairman of the Board, Video Transcript

    Francis Aguilar and Richard G. Hamermesh

    Transcript for Video (9-882-524).

    Keywords: Industrial Products Industry;

    Citation:

    Aguilar, Francis, and Richard G. Hamermesh. "General Electric: John F. Welch, Jr., Chairman of the Board, Video Transcript." Harvard Business School Video Supplement 383-002, June 1983.  View Details
    CiteView DetailsPurchase Related
  194. Case | HBS Case Collection | December 1974 (Revised May 1983)

    Fuqua Industries (A)

    Malcolm S. Salter and Richard G. Hamermesh

    Citation:

    Salter, Malcolm S., and Richard G. Hamermesh. "Fuqua Industries (A)." Harvard Business School Case 375-189, December 1974. (Revised May 1983.)  View Details
    CiteView DetailsFind at Harvard Related
  195. Supplement | HBS Case Collection | September 1977 (Revised May 1983)

    BiC Pen Corp. (A), Supplement

    Richard G. Hamermesh

    Supplements the (A) case.

    Keywords: Consumer Products Industry;

    Citation:

    Hamermesh, Richard G. "BiC Pen Corp. (A), Supplement." Harvard Business School Supplement 378-086, September 1977. (Revised May 1983.)  View Details
    CiteView DetailsPurchase Related
  196. Supplement | HBS Case Collection | April 1983

    International Harvester: Comments on Tenure as CEO, Video

    Richard G. Hamermesh

    Citation:

    Hamermesh, Richard G. "International Harvester: Comments on Tenure as CEO, Video." Harvard Business School Video Supplement 883-517, April 1983.  View Details
    CiteView DetailsFind at Harvard Related
  197. Supplement | HBS Case Collection | July 1982

    General Electric: Strategic Planning, Corporate Goals, and the Job of the Chief Executive, Video

    Richard G. Hamermesh and Francis Aguilar

    Introduces Reginald Jones, former CEO of General Electric. Presents a question and answer session with Jones and Advanced Management Program participants.

    Keywords: Managerial Roles; Corporate Strategy; Strategic Planning; Goals and Objectives;

    Citation:

    Hamermesh, Richard G., and Francis Aguilar. "General Electric: Strategic Planning, Corporate Goals, and the Job of the Chief Executive, Video." Harvard Business School Video Supplement 883-504, July 1982.  View Details
    CiteView DetailsPurchase Related
  198. Supplement | HBS Case Collection | April 1982

    General Electric: John F. Welch, Jr., Chairman of the Board, Video

    Francis Aguilar and Richard G. Hamermesh

    Welch discusses a variety of topics.

    Keywords: Management Teams; Governing and Advisory Boards; Spoken Communication; Industrial Products Industry;

    Citation:

    Aguilar, Francis, and Richard G. Hamermesh. "General Electric: John F. Welch, Jr., Chairman of the Board, Video." Harvard Business School Video Supplement 882-524, April 1982.  View Details
    CiteView DetailsPurchase Related
  199. Supplement | HBS Case Collection | June 1981

    International Harvester: The First Two Years, Video

    Richard G. Hamermesh

    Keywords: Agribusiness; United States;

    Citation:

    Hamermesh, Richard G. "International Harvester: The First Two Years, Video." Harvard Business School Video Supplement 881-504, June 1981.  View Details
    CiteView DetailsFind at Harvard Related
  200. Supplement | HBS Case Collection | June 1981

    International Harvester: Future Prospects and the Strike, Video

    Richard G. Hamermesh

    Citation:

    Hamermesh, Richard G. "International Harvester: Future Prospects and the Strike, Video." Harvard Business School Video Supplement 881-505, June 1981.  View Details
    CiteView DetailsFind at Harvard Related
  201. Case | HBS Case Collection | November 1980 (Revised April 1981)

    International Harvester (B2)

    Richard G. Hamermesh and Evelyn T. Christiansen

    Keywords: Manufacturing Industry; Agriculture and Agribusiness Industry;

    Citation:

    Hamermesh, Richard G., and Evelyn T. Christiansen. "International Harvester (B2)." Harvard Business School Case 381-054, November 1980. (Revised April 1981.)  View Details
    CiteView DetailsFind at Harvard Related
  202. Case | HBS Case Collection | November 1980 (Revised March 1981)

    International Harvester (B4)

    Richard G. Hamermesh and Evelyn T. Christiansen

    Keywords: Manufacturing Industry; Agriculture and Agribusiness Industry;

    Citation:

    Hamermesh, Richard G., and Evelyn T. Christiansen. "International Harvester (B4)." Harvard Business School Case 381-056, November 1980. (Revised March 1981.)  View Details
    CiteView DetailsFind at Harvard Related
  203. Case | HBS Case Collection | November 1980 (Revised March 1981)

    International Harvester (C)

    Richard G. Hamermesh and Evelyn T. Christiansen

    Keywords: Agriculture and Agribusiness Industry; Manufacturing Industry;

    Citation:

    Hamermesh, Richard G., and Evelyn T. Christiansen. "International Harvester (C)." Harvard Business School Case 381-057, November 1980. (Revised March 1981.)  View Details
    CiteView DetailsFind at Harvard Related
  204. Case | HBS Case Collection | November 1980

    International Harvester (B3)

    Richard G. Hamermesh and Evelyn T. Christiansen

    Keywords: Agriculture and Agribusiness Industry; Manufacturing Industry;

    Citation:

    Hamermesh, Richard G., and Evelyn T. Christiansen. "International Harvester (B3)." Harvard Business School Case 381-055, November 1980.  View Details
    CiteView DetailsFind at Harvard Related
  205. Case | HBS Case Collection | February 1979 (Revised October 1980)

    Mitek Corp.

    Richard G. Hamermesh and Evelyn T. Christiansen

    Citation:

    Hamermesh, Richard G., and Evelyn T. Christiansen. "Mitek Corp." Harvard Business School Case 379-110, February 1979. (Revised October 1980.)  View Details
    CiteView DetailsFind at Harvard Related
  206. Case | HBS Case Collection | March 1980 (Revised May 1980)

    Management Succession and Board Membership

    Richard G. Hamermesh

    Keywords: Management Succession; Governing and Advisory Boards;

    Citation:

    Hamermesh, Richard G. "Management Succession and Board Membership." Harvard Business School Case 380-132, March 1980. (Revised May 1980.)  View Details
    CiteView DetailsFind at Harvard Related
  207. Teaching Note | HBS Case Collection | April 1980

    Management Succession and Board Membership, Teaching Note

    Richard G. Hamermesh

    Keywords: Management Succession; Governing and Advisory Boards;

    Citation:

    Hamermesh, Richard G. "Management Succession and Board Membership, Teaching Note." Harvard Business School Teaching Note 380-187, April 1980.  View Details
    CiteView Details Related
  208. Supplement | HBS Case Collection | February 1979

    Mitek Corp., Supplement

    Richard G. Hamermesh and Evelyn T. Christiansen

    Citation:

    Hamermesh, Richard G., and Evelyn T. Christiansen. "Mitek Corp., Supplement." Harvard Business School Supplement 379-111, February 1979.  View Details
    CiteView DetailsFind at Harvard Related
  209. Teaching Note | HBS Case Collection | June 1978

    Bishopric, Inc., Teaching Note

    Richard G. Hamermesh

    Citation:

    Hamermesh, Richard G. "Bishopric, Inc., Teaching Note." Harvard Business School Teaching Note 378-279, June 1978.  View Details
    CiteView Details Related
  210. Case | HBS Case Collection | October 1977

    Bishopric, Inc.

    Richard G. Hamermesh

    Citation:

    Hamermesh, Richard G. "Bishopric, Inc." Harvard Business School Case 378-025, October 1977.  View Details
    CiteView DetailsFind at Harvard Related
  211. Case | HBS Case Collection | December 1974 (Revised April 1975)

    Fuqua Industries (C)

    Malcolm S. Salter and Richard G. Hamermesh

    Citation:

    Salter, Malcolm S., and Richard G. Hamermesh. "Fuqua Industries (C)." Harvard Business School Case 375-191, December 1974. (Revised April 1975.)  View Details
    CiteView DetailsFind at Harvard Related
  212. Supplement | HBS Case Collection | December 1974

    Fuqua Industries (B)

    Malcolm S. Salter and Richard G. Hamermesh

    Citation:

    Salter, Malcolm S., and Richard G. Hamermesh. "Fuqua Industries (B)." Harvard Business School Supplement 375-190, December 1974.  View Details
    CiteView DetailsFind at Harvard Related

Other Publications and Materials

  1. Article | Harvard Business Review (website)

    The Harvard Contest That's Trying to Improve Health Care Delivery

    Richard G. Hamermesh, Robert S. Huckman, Barbara McNeil, Joseph P. Newhouse and Cara Sterling

    Citation:

    Hamermesh, Richard G., Robert S. Huckman, Barbara McNeil, Joseph P. Newhouse, and Cara Sterling. "The Harvard Contest That's Trying to Improve Health Care Delivery." Harvard Business Review (website) (October 2, 2015). (As part of Measuring Costs and Outcomes in Health Care, a collaboration of the editors of Harvard Business Review and the New England Journal of Medicine.)  View Details
    CiteView Details Register to Read Related

        Richard G. Hamermesh In the News

        21 Jun 2017
        Harvard Business Review
        A New Approach to Safely Sharing Cancer Patients’ Data
        13 Apr 2017
        Forbes
        What Precision Medicine Can Learn from the NFL
        14 Feb 2017
        FiercePharma
        Want to build better patient relationships? Take a page from consumer marketers, advises Harvard fellow
        11 Jan 2017
        STAT
        How do we solve the crisis in cancer communication?
        12 Jan 2017
        Harvard Business Review
        What Cancer Researchers Can Learn from Direct-to-Consumer Companies
        28 Nov 2016
        Harvard Business Review
        One Obstacle to Curing Cancer: Patient Data Isn’t Shared
        28 Jan 2016
        Pharmaceutical Executive
        Harvard Business School Launches Precision Trials Challenge
        06 Jan 2016
        Cold Call
        A Microchip in Your Medicine
        18 Nov 2015
        Poets & Quants
        NFL Owner Kraft Gives HBS $20 Million
        05 Nov 2015
        Cold Call
        The Long Run: the Impact of Brain Injuries on the NFL
        02 Oct 2015
        Harvard Business Review
        The Harvard Contest That’s Trying to Improve Health Care Delivery
        10 Mar 2015
        Journal of the American Medical Association
        Innovation and Implementation in Cardiovascular Medicine
        04 Mar 2015
        Labratory Equipment
        Challenging the Rate of Digital Health Care
        20 Nov 2014
        Harvard Business School
        Finalists Announced in Harvard Business School-Harvard Medical School Health Acceleration Challenge
        18 Aug 2014
        HBS Working Knowledge
        Have a Better Idea To Improve Health Care?
        05 Dec 2013
        HBS Working Knowledge
        Encourage Breakthrough Health Care by Competing on Products Rather Than Patents
        20 Sep 2010
        HBS Alumni Bulletin
        RX for Change
        27 Apr 2010
        International Herald Tribune
        Nurturing Leaders for Health Care

        Additional Information (Links)

        • Making a Difference in Healthcare
        • Kraft Precision Medicine Accelerator
        • @RHamermesh on Twitter

        Areas of Interest

        • entrepreneurial management
        • healthcare ventures
        • intellectual property
        • leadership

        Additional Topics

        • corporate entrepreneurship
        • corporate governance
        • corporate social responsibility
        • corporate venturing
        • entrepreneurship
        • experimentation
        • general management
        • growth management
        • innovation
        • IPO
        • joint ventures
        • leveraged buyouts
        • managing growth
        • patents
        • small company management
        • startup management
        • technological change
        • venture creation/development

        Industries

        • health care
        MORE
        ǁ
        Campus Map
        Campus Map
        Harvard Business School
        Soldiers Field
        Boston, MA 02163
        → Map & Directions
        → More Contact Information
        → More Contact Information
        → More Contact Information
        → More Contact Information
        • HBS Facebook
        • Alumni Facebook
        • Executive Education Facebook
        • Michael Porter Facebook
        • Working Knowledge Facebook
        • HBS Twitter
        • Executive Education Twitter
        • HBS Alumni Twitter
        • Michael Porter Twitter
        • Recruiting Twitter
        • Rock Center Twitter
        • Working Knowledge Twitter
        • Jobs Twitter
        • HBS Youtube
        • Michael Porter Youtube
        • Executive Education Youtube
        • HBS Linkedin
        • Alumni Linkedin
        • Executive Education Linkedin
        • MBA Linkedin
        • Linkedin
        • HBS Google Plus
        • Executive Education Google Plus
        • HBS Instagram
        • Alumni Instagram
        • Executive Education Instagram
        • Michael Porter Instagram
        • HBS iTunes
        • Executive Education iTunes
        • HBS Tumblr
        • Executive Education Weibo
        • HBS Snapchat
        • Executive Education Wechat
        • →All Social Media
        • → All Social Media
        • Site Map
        • Jobs
        • Harvard University
        • Trademarks
        • Policies
        • Accessibility
        • Terms of Use
        Copyright © President & Fellows of Harvard College